Publications:

Peer-Reviewed Journals
Other Publications
Abstracts & Presentations

Articles in Peer-Reviewed Journals

  • Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, René duPont Christensen, Zoltán Novák, Destin Black, Lucy Gilbert, Sudarshan Sharma, Giorgio Valabrega, Lisa M, Landrum, Lars C. Hanker, Ashlet Stuckey, Ingrid Boere, Michael A Gold, Annika Auranen, Bhavana Pothuri, David Cibula, Carolyn McCourt, Franscesco Raspagliesi, Mark S. Shahin, Sara E. Gill, Bradley J. Monk, Joseph Buscema, Thomas J Herzog, Larry J Copeland, min Tian, Zangdong He, Shadi Stevens, Efetherios Zografos, Robert L Coleman, Matthew A. Powell. A Plain Language Summary of “Dostarlimab for primary advanced or recurrent endometrial cancer”, Future Oncology [submitted Nov 3, 2023]
  • Thierry André, Dominique Breton, Giuseppe Curgliano, Renaud Sabatier, Anna V. Tinker, Ana Oaknin, Susan Ellard, Filippo de Braud, Hendrik-Tobias Arkenau, Jose Trigo, Adriano Gravina, Rebecca Kristeleit, Victor Moreno, Cyril Abdeddaim, Yann-Alexandre Vano, Vanessa Samouëlian, Rowan Miller, Valentina Boni, Antonio Antón Torres, Lucy Gilbert, Jubilee Brown Ninad Dewal, Christine Dabrowski, Gracy Antony, Eleftherios Zografos, Jennifer Veneris, Susana Banerjee. Antitumor Activity and Safety of Dostarlimab Monotherpay in Patients With Mismatch Repair Deficient Solid Tumors – A Nonrandomized Controlled Trial, JAMA Network Open 2023;6(11):e2341165., November 2, 2023, https://doi:10.100/jamanetworkopen.2023.41165
  • Thomas J Nerzog, John L Hays, Joyce N Barlin, Joseph Buscema, Noelle G Cloven, Lynn R Kong, Nidhi Kumar Tyagi, Grainger S Lanneau, Beverly J Long, Robert L Marsh, Shelly M Seward, David C Starks, Stphen Welch, Kathleen N Morre, Panagiotis A Konstantiopoulos, Lucy Gilbert, Bradley J Monk, David M O’Malley, Xiei Chen, Rita Dalal, Roberty L Coleman, Jalid Sehouli, on behalfof the Artistry-7 Study Team. ARTISTRY-7: PhaSE III trial of nembaleukin alfa plus pembrolizumag vs cheomtherpay for platinum-resistant ovarian cancer, Future Oncology 19(23): 1577-1639, July 2023, https://doi.org/140.2217/fon-2023-0246
  • Mame Daro Faye, Mariana Petruccelli Araujo, Michel D Wissing, Khalid Alrabiah, Lucy Gilbert, Xing Zeng, Luis Souhami, Joanne Alfieri. Safety and Efficacy of 2D Brachytherapy for Locally Advanced Cervical Cancer – A Single Institutuion Retrospective Study, Current Oncology, 2023, 30, https://doi.org/10.3390/xxxxx.
  • Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, Jubilee Brown, Sharad Ghamande, Cara Mathews, David O’Malley, Rebecca Kristeleit, Valentina Boni, Adriano Gravina, Susana Banerjee, Rowan Miller, Joanna Pikiel, Mansoor Mirza, Ninad Dewal, Grace Antony, Yuping Dong, Eleftherios Zografos, Jennifer Taylor Veneris, and Anna Tinker. Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study. Clinical Cancer Research. 2023 [in press].
  • Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O’Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C III, Dong Y, Veneris J, Pothuri, B. A Plain Language Summary of Results from the GARNET Study of Dostarlimab in Patients with Endometrial Cancer. Future Oncology 2023 Aug; 19 (25): 1709-1714 doi: 10.2217/fon-2022-1157, E-pub Jun 29, 2023
  • L’Espérance K, Grundy A, Abrahamowicz M, Arseneau J, Gilbert L, Gotlieb WH, Provencher D, Koushik A. Alcohol intake and the risk of epithelial ovarian cancer. Cancer Causes Control 2023; [in press]
  • Mirza MR, Chase Dana, Slomovitz B, Christensen RD, Novak Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum L, Haner LG, Stuckey A, Boere I, Gold M, Auranen A, Pothuri B, Cibula D, McCourt C, Raspaglies F, Shahin MS, Gill S, Monk B, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell M. Dostarlimab Plus Chemotherapy for Primary Advanced or Recurrent Endometrial Cancer, N Engl J Med. March 27, 2023. DOI: 10.1056/NEJMoa2216334
  • Lucy Gilbert, Ana Oaknin, Ursula A Matulonis, Gina M. Mantia-Samldone, Peter Lim, Cesar M. Castro, Diane Provencher, Sanaz Memarzadeh, Michael Method, Jiuzhou Wang, Kathleen N. Moore, David M. O’Malley. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer, Gynecologic Oncology, 170: 241-247, March 2023. https://doi.org/10.1016/j.ygyno.2023.01.020
  • Ainhoa Madariaga, Swati Garg, Nairi Tchrakian, Neesa Chani, Waldo Jimenez, Stephen Welch, Helen MacKay, Josee-Lyne Ethier, Lucy Gilbert, Xuan Li, Angela Rodriguez, Lucy Chan, Valerie Bowering, Blaise Clarke, Tong Zhang, Ian King, Gregory Downs, Tracy Stockley, Lisa Wand, Smitha Udagani, Amit Oza, Stephanie Lheureux. Clinical outcome and biomarker assessments of a multi-centre phase II trail assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma, Nature Communications [in press March 2, 2023, NCOMMS-22-31116B
  • Karen Cadoo, Fiona Simpkins, Cara Mathews, Ying L. Liu, Diane Provencher, Colleen McCormick, Adam C. EINagger, Alon Dr. Altman, Lucy Gilbert, Destin Black, Nashwa Kabil, James Bennet, Jiefen Muncley, Carol Aghajanian. Olaparib Treatment for Platinum-Sensitive Relapsed Ovarian Cancer by BRCA Mutation and Homologous Recombination Deficiency Status: Phase II LIGHT Study Primary Analysis, Gynecol Oncology, 166 (3): 425-431, September 2022. https://doi.org/10.1016/j.ygyno.2022.06.017
  • Ana Oaknin, Lucy Gilbert, Anna V. Tinker, Jubilee Brown, Cara Mathews, Joshua Press, Renaud Sabatier, David M. O.Malley, Vanessa Samouliën, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatage, Rebecca Kristeleit, Charles Leath III, Yuping Dong, Jennifer Veneris, Bhavana Potthuri. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability – high (dMMR/MSI) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET – a phase I, single arm study, Plain Language Study, Journal for ImmunoTherpay of Cancer. 2022 Jan;10(1):e003777, doi: 10.1136/jitc-2021-003777
  • Ainhoa Madariaga, Swati Garg, Nairi Tchrakian, Neesha C. Dhani, Waldo Jimenz, Stephen Welch, Helen MacKay, Josee-Lyne Ethier, Lucy Gilbert, Xuan Li, Angela Rodriguez, Lucy Chan, Valerie Bowering, Blaise Clarke, Tong Zhang, Ian King, Tracy Stockley, Lisa Wang, Smitha Udagani, Amit M. Oza, Stephanie LHeureux. Multi-centre phase II trial assessing niraparib with or without dostarlimab (anti-PD-1) in recurrent endometrial carcinoma: Clinical outcome and biomarkers assessments, Clinical Cancer Research [submitted June 27, 2022 – CCR-22-2005]
  • ALMuhizi Faisal, Leticia De Las Vecillas Sanchez, Lucy Gilbert, Ana M Copaescu, Ghislaine A. C. Isabwe. Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherpay : a literature review, Clinical Reviews in Allergy and Immunology, Published online March 08, 2022. https://doi.org/10.1007/s12016-022-08932-2
  • Amuzu S, Fu L, Demko N, Rivera B, Domecq C, de Kock L, Hamel N, Gilbert L, Polak P, Ragoussis J, Foulkes WD. Long-term tumor dormancy in a BRCA1 heterozygote, J Med Genet. 2022;0, 1-3. http://dx.doi.org/10.1136/jmedgenet-2021-108269
  • Ana Oaknin, Lucy Gilbert, Anna V Tinker, Jubilee Brown, Cara Mathews, Joshua Press, Renaud Sabatier, David M O’Malley, Vanessa Samouelian, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatage, Rebecca Kristeleit, Charles Leath III, Wei Guo, Ellie Im, Sybil Zildjian, Xinwei Han, Tao Duan, Jennifer Veneris, Bhavana Pothuri. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability- high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET- a phase I single-arm study, Journal for Immunotherapy of Cancer 2022;10:e003777. (13/12/2021) https://doi:10.1136/jitc-2021-003777
  • Christian Marth, Rafal Tarnawski, Alexandra Tyulyandina, Sandro Piginata, Lucy Gilbert, Diego Kaen, M Jesús Rubio, Sophia Frentzas, Mario Beiner, Manuel Magallanes-Maciel, Laura Farrelly, Chel Hun Choi, Regina Berger, Christine Lee, Christof Yulsteke, Kosei Hasegawa, Elena Braicu, Xiaohua Wu, Jody McKenzie, John J Lee, Vicky Makker. Phase 3, randomized, open label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001, Int J Gynecol Cancer;0:1-7. (13-10-2021) https://Doi:10.1136/ijc-2021-003017
  • Ana Oaknin, Anna V. Tinker, Lucy Gilbert, Vanessa Samouëlian, Cara Mathews, Jubilee Brown, Maria-Pilar Barretina-Ginesta, Victor Moreno, Adriano Gravina, Cyril Abdeddaim, Susana Banerjee, Wei Guo Hadi Danaee, Ellie Im, Renaud Sabatier. PLS – Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: results from part 2B of a phase 1 clinical trial, Future Oncology 2021 Oct 1;17(29):3781-3785. (24/08/2021) https://doi: 10.2217/fon-2021-0598
  • Ignace Vergote, Isabelle Ray-Coquard, Daniel M Anderson, Guilherme Cantuaria, Nicoletta Colombo, Claire Garnier-Tixidre, Lucy Gilbert, Philpp Harter, Robert Hettle, Domenica Lorusso, Johanna Mäenpää, Christian Marth, Koji Matsumoto, Mario Ouwens, Andrés Poveda, Franceso Raspagliesi, Kirsty Rhodes, Maria Jesus Rubio Pérez, Ronnie Shapira-Frommer, Aymi Shikama, Magdalena Sikorska, Kathleen Moor, Paul DiSilvestro. Popluation – adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluation maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer, European Journal of Cancer 157 (2021)415-423. (18/08/2021) https://Doi.org/10.1016/j.ejca.2021.08.023
  • Thierry Alcindor, Sungmi Jung, Lucy Gilbert. Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report Curr. Oncol. 2021 Jun10;28(3), 2146-2149; https://doi.org/10.3390/curroncol28030199. PMID: 34200874
  • Shirin M Shallwani, Anna Towers, Anne Newman, Shannon Salvador, Angela Yung, Lucy Gilbert, Walter Gotlieb, Ziggy Zeng, Doneal Thomas. Feasibility of a pilot randomized controlled trial evaluating a multidimensional intervention in women with gynecologic cancer at risk of lymphedema, Curr. Oncol, 2021, 28 (1), 455-470, January 13, 2021. https: //doi/10.3390/curroncol28010048
  • Mariam El-Zein, Walter Gotlieb, Lucy Gilbert, Robert Hemmings, Marcel A. Behr, Eduardo L. Franco, for the STAIN-IT study group. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing (STAIN-IT) study, International Journal of Cancer (2021) 148 (2):492-501, January 15, 2021. https://doi.org/10.1002/ijc.33250
  • Lucy Gilbert, Kyle Miller, Diogo Medeiros, Maria Tsatoumas, Anthony Ciarallo, Chislaine Isabwe, Joelle Malek, Vivian G Loo, Princy Kumar. A disease that disregards anatomical planes more so than cancer – Clinical Picture, The Lancet (2020) 396: 1766, November 28, 2020.
  • Ana Oaknin, Anna V Tinker, Lucy Gilbert, Vanessa Samouëlian, Cara Mathews, Jubilee Brown, Maria-Pilar Barretina-Ginesta, Victor Moreno, Adriano Gravina, Cyril Abdeddaim, Susana Banjerjee, Wei Guo, Hadi Danaee, Ellie Im, and Renaud Sabatier. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair – Deficient Endometrial Cancer a Nonrandomized Phase 1 Clinical Trial, Jama Oncology, Nov 2020 6(11):1766-1772. doi: 10.1001/jamaoncolo.2020.4515
  • *Sabrina Piedimonte, Joanne Power, William D Foulkes, Evan Weber, Laura Palma, Alicia Schiavi, Rea Konci, Enza Ambrosio, Lucy Gilbert, Kris Jardon, Laurence Baret, Xing Ziggy Zeng. BRCA Testing in women with high grade serous ovarian cancer: gynecologic oncologist initiated testing compared to genetics referral, International Journal of Gynecologic Cancer (2020), 30:1757-1761. doi:10.1136/ijgc-2020-001261
  • Lucy Gilbert, Agnihotram V Ramanakumar, Maria Carolina Festa, Kris Jardon, Xing Zeng, Claudia Martins, Layla Shbat, Marwa Abo Alsoud, Manuel Borod, Micheal Wolfson, Olga Basso, John Sampalis. Real – World Health Economic Assessment of Treating Recurrent High-Grade Serous Ovarian Cancer with Cytotoxic Chemotherapy, Journal of Comparative Effectiveness Research (2020) 9 (8): 537-551. https://doi.org/10.2217/cer-2020-0032
  • David, O’Malley, Ursula A Matulonis, Michael J Birrer, Cesar M Castro, Lucy Gilbert, Ignace Vergote, Lainie P Martin, Gina M Mantia-Smaldone, Antonio Gonzalez Martin, Raquel Bratos, Richard T Penson, Karim Malek, Kathleen N Moore. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR<alpha>)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer, Gynecologic Oncology, 157 (2): 379-385, May 2020. https://doi.org/10.1016/j.ygyno.2020.01.037
  • Mariam El-Zein, David Cheishvili, Walter Gotlieb, Lucy Gilbert, Robert Hemmings, Marcel A. Behr, Moshe Szyf, Eduardo L. Franco, for the MARKER study group. Genome-wide DNA methylation profiling identifies two novel genes in cervical neoplasia, International Journal of Cancer, 147 (5), 1264-1274, Jan 2020. https://doi.org/10.1002/ijc.32880
  • Isabelle Ray-Coquard, David Cibula, Mansoor R. Mirza, Alexander Reuss, Caterina Ricci, Nicoletta Colombo, Horst Koch, Frédéric Goffin, Antonio González-Martin, Petronella B. Ottevanger, Klaus Baumann, Line Bjørge, Anne Lesoin, Alexander Burges, Per Rosenberg, Martina Gropp-Meier, Maija Harrela, Philipp Harter, Jean-Sébastien Frenel, Tomas Minarik, Carmela Pisano, Annette Hasenburg, Michael Merger, Andreas du Bois, Lucy Gilbert as on behalf of the AGO Study Group-led GCIG/ENGOT Intergroup Consortium (Lucy Gilbert Collaborator). Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer, International Journal of Cancer, 146 (2):439-448, Jan 15, 2020. https://doi.org/10.1002/ijc.32606
  • Grundy A, Ho, V, Abrahamowicz M, Parent M-E, Siemiatycki J, Arseneau J, Gilbert L, Gotlieb W H, Provencher D, Koushik A. Lifetime recreational moderate –to-vigorous physical activity and ovarian cancer risk: a case-control study, International Journal of Cancer, 2020 Apr 1;146(7):1800-1809. doi: 10.1002/ijc.32513 Epub 2019 Jul 1
  • Mariam El-Zein, David Cheishvili, Walter Gotlieb, Lucy Gilbert, Robert Hemmings, Marcel A. Behr, Moshe Szyf, Eduardo L. Franco, for the MARKER study group. Genome-wide DNA methylation profiling identifies two novel genes in cervical neoplasia, International Journal of Cancer, 147 (5), 1264-1274, Jan 2020. https://doi.org/10.1002/ijc.32880
  • Talía Malagón, Karolina Louvanto, Agnihotram V. Ramanakumar, Anita Koushik, François Coutlée, Eduardo L. Franco, Biomarkers of Cervical Cancer Risk Study Team (clinical colloaborator L.Gilbert). Gynecologic Oncology, 155 (2) Nov 2019: 245-253. https://doi.org/10.1016/j.ygyno.2019.09.010
  • Josep M. del Campo, Ursula A. Matulonis, Susanne Malander, Diane Provencher, Sven Mahner, Philippe Follana, Justin Waters, Jonathan S. Berek, Kathrine Woie, Amit M. Oza, Ulrich Canzler, Marta Gil Martin, Anne Lesoin, Bradley J Monk, Bente Lund, Lucy Gilbert, Robert M. Wenham, Benedict Benigno, Sujata Arora, Sebastien J. Hazard, Mansoor R. Mirza. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer Following a Partial
  • Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial, Journal of Clinical Oncology, Jun 2019, 37 (32): 2968-2973. doi 10.1200/JCO.18.02238
  • Lisa Leung, Anne Grundy, Jack Siemiatycki, Jocelyne Arseneau, Lucy Gilbert, Walter H Gotlieb, Diane Provencher, Kristan J Aronson, Anita Koushik. Shift Work Patterns, Chronotype, and Epithelial Ovarian Cancer Risk, Cancer Epidemiology, Biomarkers & Prevention, March 6, 2019, 28 (5): 987-995. https:// doi: 10.1158/1055-9965.EPI-18-1112
  • El-Zein M, Bouten S, Louvanto K, Gilbert L, Gotlieb WH, Hemmings R, Behr MA, Franco El; Cassis Study Group. Cancer Epidemiol Biomarkders Prev. 2019 Jul;28(7)”1134-1140. Doi 10.1158/1055-9965.EPI-1338. Epub 2019 Apr 23.PMID:31015201
  • Matulonis UA, Birrer MJ, O’Malley DM, Moore KN, Konner J, Gilbert L, Martin LP, Bauer TM, Oza AM, Malek K, Pinkas J, Kim SK. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirevtuximab Soravtansine, Clinical Cancer Research, Nov 8, 2018;25(6):1727-1736. doi: 10.1158/1078-0432.ccr-18-2474
  • *Albeesh R, Turgeon G-A, Alfieri J, Mansure JJ, Fu L, Arseneau J, Zeng Z, Jardon K, Gilbert L, Souhami L. Adjuvant therapy in stage III endometrial cancer confined to the pelvis, Gynecologic Oncology 2019;152(1): 26-30. doi.org/10.1016/j.ygyno.2018.11.002
  • *Piedimonte S, Richer A, Souhami L, Arseneau J, Fu L, Alfieri J, Gilbert L, Jardon K, Zeng X. Clinical Significance of Isolated Tumor Cells in Endometrial Cancer. October 24, 2018, Journal of Surgical Oncology, 7 (118): 1194-1198. doi: 10.1002/jso.25259
  • Eduardo Franco, Mariam El-Zein, Sheila Bouten, Karolina Louvanto, Lucy Gilbert, Walter Gotlieb, Robert Hemmings, Marcel A Behr. Validation of a new HPV self-sampling device for cervical cancer screening: the Cervical and Self-Sample In Screening (CASSIS) study, Gynecologic Oncology, 2018; 3 (149): 491-497. https:// doi.org/10.1016/j.ygyno.2018.04.004
  • *Yuxuan Wang, Lu Li, Christopher Douville, Joshua D. Cohen, Isaac Kinde, Karin Sundfelt, Susanne Krüger Kjær, Ie-Ming Shih, Tian-Li Wang, Robert Kurman, Simeon Springer, Janine Ptak, Maria Popoli, Joy Schaefer, Natalie Silliman, Lisa Dobbyn, Ting-Tai Yen, Maria Lycke, Kirsten Jochumsen, Bahman Afsari, Douglas Levine, Kris Jardon, Xing Zeng, Jocelyne Arseneau Lili Fu, Luis A. Diaz Jr., Rachel Karchin, Cristian Tomasetti, Kenneth W. Kinzler, Bert Vogelstein, Amanda N. Fader, Lucy Gilbert, Nick Papadopoulos. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers, 21 March 2018, Sci. Transl. Med. 10 (433):1-9; eaap8793 (2018). https:// doi: 10.1126/scitranslmed.aap8793
  • Gilbert L, Revil T, Meunier C, Jardon K, Zeng X , Martins C, Arseneau J, Fu L, North K, Schiavi A, Ehrensperger E, Artho G, Todd L, Morris D, Ragoussis J. The Empress of Subterfuge: cancer of the fallopian tube presenting with malapropism. The Lancet, Sep 2017; 390 (10098):1003-1004. Doi: http://dx.doi.org/10.1016/S0140-6736(17)31586-6
  • *Sun Z, Gilbert L, Ciampi A, Basso O. Recruitment challenges in clinical research survey of potential participants in a diagnostic study of ovarian cancer, Gynecology Oncology, Sep 2017;146(3):470-476. doi: 1016/j.ygyno.2017.06.21
  • Ueno Y, Forghani B, Forghani R, Dohan A, Zeng XZ, Chamming’s F, Arseneau J, Fu L, Gallix B, Gilbert L, Reinhold C. Endometrial Carcinoma: MR Imaging-based Texture Model for Preoperative Risk Stratification –A Preliminary Analysis, Radiology, Sep 2017; 284(3): 748-757. doi: org/10.1148/radiol.2017161950. Epub 2017 May 10.PMID: 28493790
  • Koushik A, Grundy A, Abrahamowicz M, Arseneau J, Gilbert L, Gotlieb W H, Lacaille J, Mes-Masson AM, Parent MÉ, Provencher DM, Richardson L, Siemiatycki J. Hormonal and reproductive factors and the risk of ovarian cancer. Cancer Causes Control. May 2017; 28(5):393-403. doi: 10.1007/s10552-016-0848-9. PubMed PMID: 28102526
  • *Sun Z, Gilbert L, Ciampi A, Kaufman J, Basso O. Estimating the prevalence of ovarian cancer symptoms in women aged 50 and older: problems and possibilities. American Journal of Epidemiology, October 2016; 184(9):670-680. doi: 10.1093/aje/kww086
  • Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, Amit M. Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A. Ledermann, Domenica Lorusso, Ignace Vergote, Noa Efrat Ben-Baruch, Christian Marth, Radosław Mądry, René dePont Christensen, Jonathan S. Berek, Anne Dørum, Anna V. Tinker, Andreas du Bois, Antonio González Martín, Philippe Follana, Benedict Benigno, Per Rosenberg, Lucy Gilbert, Bobbie J. Rimel, Joseph Buscema, John P. Balser, Shefali Agarwal, Ursula A. Matulonis. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer, New England Journal of Medicine, October 2016, 375(22): 2154-2164. doi: 10.1056/NEJMoa1611310
  • Huisman MG, Veronese G, Audisio RA, Ugolini G, Montroni I, De Bock GH, van Leeuwen BL, Gilbert L for the Preop Study group. Poor nutritional status is associated with other geriatric domain impairments and adverse postoperative outcomes in onco-geriatric surgical patients – A multicentre cohort study. EJSO, 2016 July 42(7):1009-1017. doi.org/10.1016/j.ejso.2016.03.005
  • du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Seven E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P, the AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynecolgic Oncology Trials Groups Intergroup Consortium (L.Gilbert as collaborator) Lancet Oncology, 2016 Jan; 17(1):78-89. http://dx.doi.org 10.1016/S1470-2045(15)00366-6. Epub 2016 Nov 16
  • Martel C, Labrie F, Archer D, Ke Y, Gontheir R, Simare JN, Lavoie L, Vaillancourt M, Montesino M, Balser J, Moyneur E, Gilbert L as part of Prasterone Clinical Research Group. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5 mg intravaginal prasterone for 12 weeks. J Steroid Biochem Mol Biol. 2016 May;159:142-53. doi: 10.1016/j.jsbmb.2016.03.016. Epub 2016 Mar 10
  • Covens A, Higgins B, Verma S, Bessette P, Bin J, Hoskins P, Provencher D, Gilbert L, Ghatage P, Warr D, Majdan M, Pouliot JF, Emend®IV in salvage treatment of chemotherapy-induced vomiting: the EVADE study, Supportive Care in Cancer, May 2015
  • Spence AR, Alobaid A, Drouin P, Goggin P, Gilbert L, Provencher D, Tousignant P, Hanley JA, Franco EL. Screening histories and contact with physicians as determinants of cervical cancer risk in Montreal Quebec. Curr Oncol. 2014 Dec; 21(6): 294-304. doi: 10.3747/co.21.2056
  • *Fiset PO, Wou K, Arseneau J, Gilbert L. Vulvar Carcinosarcoma Secondary to Radiotherapy: A Case Report and Review of the Literature. J Low Genit Tract Dis 2014 Jul; 18(3):E74-9. doi: 10.1097/LGT.0b013e3182a82115
  • Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoil L, Gilbert L, Martel C, Balser J. Lack of Influence of Dyspareunia on the Beneficial Effect of Intravaginal Prasterone (Dehydroepiandrosterone, DHEA) on Sexual Dysfunction in Postmenopausal Women. J Sex Med, 2014; 11(7): 1766-85. doi: 10.1111/jsm.125.7
  • Naumann RW, Coleman RL, Burger RA, Sausville EA. Kutarska E, Ghamande SA, Gabrail NY, DePasquale SE, Nowara E, Gilbert L et al. PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol. 2013; 31 (35): 4400-6. DOI: 10.1200/JCO.2013.49.7685
  • Naumann, R. Wendel, Gilbert, Lucy, Miller, Anthonette M., Ma, Hong, Ghamande, Sharad A., Vergote, Ignace. A randomized double-blind phase III trial comparing vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD plus placebo in patients with platinum-resistant ovarian cancer (PROCEED), Journal of Clinical Oncology, 2013;31(15)
  • Gilbert L, Basso O. Screening of symptomatic women for ovarian cancer – Author’s reply. Lancet Oncol. April 2012; 13(4): e139-e140
  • Gilbert L, Basso O, Sampalis J, Karp I, Martins C, Feng J, Piedimonte S, Quintal L, Ramana-Kumar AV, Takefman J, Grigorie MS, Artho G, Krishnamurthy S, for the DOvE Study Group. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol. March 2012; 13(3): 285-91. PubMed PMID: 22257524
  • DeVries M, Agnihotram RV, Koushik A, Provencher D, Gilbert L et al. The role of environmental cofactors in the progression of cervical precancerous lesions. American Journal of Epidemiology, June 2011, 173: S169.
  • Ghamande S, Gilbert L, Penson R et al. The co-development of a folate receptor molecular diagnostic imaging agent (99mTc-EC20) and folate receptor targeted drug conjugate (EC145) in the treatment of ovarian cancer patients. European Journal of Cancer, Oct 2011: suppl 4: S8
  • Spence A, Goggin P, Drouin P, Ferenczy A, Dawes M, Provencher D, Alobaid A, Gilbert L et al. Process of care failures in women with cervical cancer. American Journal of Epidemiology, 2011; Volume: 173, June, S207.
  • Messaed C, Chebaro W, Di Roberto RB et al. (Gilbert L part of HM Collaborative Group). NLRP7 in the spectrum of reproductive wastage: rare non-synonymous variants confer genetic susceptibility to recurrent reproductive wastage. Journal of Medical Genetics 2011; 48(8): 540-548. DOI: 10.1136/jmg.2011.089144
  • Messaed C, Akoury E, Djuric U, Zeng J, Saleh M, Gilbert L, Seoud M, Qureshi S, Slim R. Molecular Bases of Disease: NLRP7, a Nucleotide Oligomerization Domain-like Receptor Protein, Is Requires for Normal Cytokine Secretion and Co-localizes with Golgi and the Microtubule-organizing Center. J Biol Chem, 2011; 286(50): 43313-23. PMID: 22025618; DOI: 10.1074/jbc.M111.306191
  • Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ. A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecologic Oncology. 2011;121(2): 273-279. PubMed PMID: 21276608; DOI: 10.1016/j.ygyno.2010.12.362
  • *Niu X, Gilbert L. Neuroendocrine carcinoma of the uterine cervix: a single institution case review. European Journal of Gynaecological Oncology, 2011; 32 (4): 377-380.
  • Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric 2011;14(2): 282–288. DOI: 10.3109/13697137.2010.535226
  • Rio Frio T, Bahubeshi A, Kanellopoulou C, Hamel N, Niedziela M, Sabbaghian N, Pouchet C, Gilbert L, O’Brien PK, Serfas K, Broderick P, Houlston RS, Lesueur F, Bonora E, Muljo S, Schimke RN, Bouron-Dal Soglio D, Arseneau J, Schultz KA, Priest JR, Nguyen VH, Harach HR, Livingston DM, Foulkes WD, Tischkowitz M. DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors. JAMA – Journal of the American Medical Association, 2011; 305(1): 68-77. DOI: 10.1001/jama.2010.1910
  • Gilbert L, Piedimonte S, Hormone Replacement Therapy and Malignances. The Canadian Journal of Diagnosis, December 2010 27(12): 58-62.
  • *Huang JY, Chian RC, Gilbert L, Fleiszer D, Holzer H, Dermitas E, Elizur SE, Gidoni Y, Levin D, Son WY, Tan SL. Retrieval of immature oocytes from unstimulated ovaries followed by in vitro maturation and vitrification: A novel strategy of fertility preservation for breast cancer
  • Patients, American Journal of Surgery, 2010;200(1):177-183. DOI: 10.1016/j.amjsurg.2009.04.004
  • Henry M, Cohen SR, Lee V, Sauthier P, Provencher D, Drouin P, Gauthier P, Gotlieb W, Lau S, Drummond N, Gilbert L, Stanimir G, Sturgeon J, Chasen M, Mitchell J, Huang LN, Ferland MK, Mayo N. The Meaning-Making intervention (MMi) appears to increase meaning in life in advanced ovarian cancer: a randomized controlled pilot study. Psycho-Oncology, 2010; 19(12): 1340-1347. DOI: 10.1002/pon.1764
  • Lachapelle J, Gilbert L, Artho G, Alcindor T, Amre R, Arseneau J and Foulkes W. Colonic or coelomic? The Lancet, 2010; 375(9728): 1844.
  • *Hancke K, Foeldi M, Zahradnik HP, Gitsch G, Gilbert L, Denschlag D. Estrogen replacement therapy after endometrial cancer: a survey of physicians’ prescribing practice. Climacteric, 2010; 13: 271-277. DOI: 10.3109/13697130903131338
  • Sohail Abu Sayeed Md, Bhattacharya, Prabir, Mudur, Sudhir P., Krishnamurthy, Srinivasan, Gilbert, Lucy, Schwenker, F., ElGayar, N. Content-Based Retrieval and Classification of Ultrasound Medical Images of Ovarian Cysts, Artificial Neural Networks in Pattern Recognition, Proceedings,2010;5998:173-184.
  • Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause, 2009; 16(5): 923-931. DOI: 10.1097/gme.0b013e31819e85c6
  • Tan, Seang Lin, Huang, Jack Yu Jen, Ata, Baris, Chian Ri-Cheng, Holzer, Hananel, Demirtas, Ezgi, Gilbert, Lucy, Dubuisson, JB, Gomel, V. In-vitro maturation and oocyte vitrification for the treatment of infertility and the preservation of fertility. Reproductive Medicine and Surgery, 2009: 33-36.
  • Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal dehydroepiandrosterone (Prasterone), the physiological and a highly efficient treatment of vaginal atrophy. Menopause, 2009; 16(5): 907-922.
  • Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Bérubé R, Bélanger P, Berger L, Gilbert L, Martel C, Balser J. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause, 2009;16(5): 897-906. DOI: 10.1097/gme.0b013e31819e8930
  • Deveault C, Qian JH, Chebaro W, Ao A, Gilbert L, Mehio A, Khan R, Tan SL, Wischmeijer A, Coullin P, Xie X, Slim R. NLRP7 mutations in women with diploid androgenetic and triploid moles: a proposed mechanism for mole formation. Hum Mol Genet. 2009;18(5): 888-897. DOI: 10.1093/hmg/ddn418
  • *Bahig H, Portelance L, Legler C, Gilbert L, Souhami L. Small cell carcinoma of the endometrium: report of a case and review of the literature. Minerva Ginecol. Aug 2009;61(4): 365-9.
  • *Chian RC, Huang JYJ, Gilbert L, Son WY, Holzer H, Cui SJ, Buckett WM, Tulandi T, Tan SL. Obstetric outcomes following vitrification of in vitro and in vivo matured oocytes. Fertility and Sterility, 2009; 91(6): 2391-2398. DOI: 10.1016/j.fertnstert.2008.04.014
  • *Chian RC, Gilbert L, Huang JYJ, Demirtas E, Holzer H, Benjamin A, Buckett WM, Tulandi T, Tan SL. Live birth after vitrification of in vitro matured human oocytes. Fertility and Sterility, 2009; 91:372-376. DOI: 10.1016/j.fertnstert.2007.11.088
  • ASTEC study group; Kitchener H et al., (Gilbert L as part of ASTEC study group). Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomized study. Lancet, 2009, 373 (9658): 125-36.
  • *Denschlag, D, Hancke, K, Zahradnik, H, Gitsch, G, Gilbert, L. Hormone replacement therapy in patients with endometrial cancer: A survey of physicians’ prescribing practice, Gynecologic Oncology, 2008, 108 (3): S48-S49
  • Henry M, Cohen SR, Virginia L, Sauthier P, Provencher, D, Drouin, P, Gauthier P, Gotlieb W, Lau S, Drummond N, Gilbert L. Randomized control trial of the Meaning-Making intervention (MMi) for people newly diagnosed with advanced ovarian cancer: a pilot study. Journal of Palliative Care, 2008; 24 (3): 198.
  • *Al-Talib A, Gilbert L, Arseneau J. Endometrioid adenocarcinoma 13 years after total abdominal hysterectomy and bilateral salpingo-oophorectomy. Saudi Medical Journal, 2008; 29(7): 1044-1047.
  • Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P, Manoukian S, Rennert G, Friedman E, Isaacs C, Rosen E, Rosen B, Daly M, Sun P, Narod SA and the Hereditary Breast Cancer Clinical Study Group. Hormone replacement therapy and the risk of breast cancer in BRCA1 mutation carriers. Journal of the National Cancer Institute, 2008; 100: 1361-1367. DOI: 10.1093/jnci/djn313
  • Palma L, Marcus V, Gilbert L, Chong G, Foulkes WD. Synchronous occult cancers of the endometrium and fallopian tube in an MSH2 mutation carrier at time of prophylactic surgery. Gynecologic Oncology, 2008; 111:575-578. DOI: 10.1016/j.ygyno.2008.08.002
  • Ades S, Koushik A, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Roger M, Franco EL. Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. International Journal of Cancer, 2008; 122(12):2820-2826. DOI: 10.1002/ijc.23459
  • *Patel S, Portelance L, Gilbert L, Tan L, Stanimir G, Duclos M, Souhami L. Analysis of prognostic factors and patterns of recurrence in patients with pathologic stage III endometrial cancer. International Journal of Radiation Oncology Biology and Physics, 2007; 68(5):1438-1445. DOI: 10.1016/j.ijrobp.2007.02.003
  • *Denschlag D, Tan L, Patel S, Kerim-Dikeni A, Souhami L, Portelance L, Duclos M, Arseneau J, Stanimir G, Gilbert L. Stage III endometrial cancer: preoperative predictability, prognostic factors, and treatment outcome. American Journal of Obstetrics and Gynecology, 2007; 196(6): 546-548. DOI: 10.1016/j.ajog.2007.01.018
  • Mayrand M, Duarte-Franco E, Rodrigues I, Walter SD, Coutlée F, Ratnam S, Franco E for the CCCaST Study Group. Comparison of Pap and HPV testing strategies for screening high-grade cervical cancer precursors: results from the Canadian Cervical Cancer Screening Trial (CCCaST). New England Journal of Medicine, 2007; 357:1579-1588, 2007 (authorship within the CCCaST Study Group as L Gilbert).
  • Garland S et al. for Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. New England Journal of Medicine, 2007; 356:1928-1943 (authorship within the FUTURE I Investigators as L Gilbert).
  • *Huang JY, Buckett W, Gilbert L, Stanimir G, Tan SL, Chian RC. Retrieval of immature oocytes followed by in-vitro maturation and vitrification of oocytes: A new possibility for fertility preservation in women with borderline ovarian malignancy. Gynecologic Oncology, 2007; 105(2):542-544. DOI: 10.1016/j.ygyno.2007.01.036
  • Schaffer A, Koushik A, Trottier H, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Pollak MN, Franco E. for the Biomarkers of Cervical Cancer Risk (BCCR) Study Team. Insulin-like growth factor-I and risk of high grade cervical intraepithelial neoplasia. Cancer Epidemiology, Biomarkers & Prevention, 2007; 16(4):716-722. DOI: 10.1158/1055-9965.epi-06-0924
  • *Sagr ER, Denschlag D, Kerim-Dikeni A, Stanimir G, Gilbert L. Prognostic Factors and Treatment related Outcome in Patients with Uterine Papillary Serous Carcinoma. Anticancer Research, 2007; 27(2):1213-1217.
  • Henry, Melissa, Cohen, S Robin, Lee, Virginia, Mayo, Nancy, Gotlieb, Walter, Lau, Suzy, Drummond, Nancy, Gilbert, Lucy, Stanimir, Gerald, Sturgeon, Jeremy, Chasen, Martin, Sauthier, Phillipe, Provencher, Diane, Drouin, Pierre, Gautier, Phillippe. Randomized control trial of the meaning-making intervention in people newly diagnosed with advanced ovarian cancer: A pilot study, Journal of Palliative Care 2007,23(3):199.
  • *Denschlag D, Masoud I, Stanimir G, Gilbert L. Prognostic factors and outcome in women with uterine sarcoma: A comparison between endometrial stromal sarcoma, Leiomyosarcoma and mixed mullerian tumors. European Journal of Surgical Oncology, 2007; 33(1):91-95. DOI: 10.1016/j.ejso.2006.11.012
  • *Patel, S, Gilbert, L, Portelance, L, Stanimir, G, Souhami, L. Analysis of prognostic factors and patterns of recurrence in patients with pathologic stage III endometrial cancer confined to the pelvis, Radiotherapy and Oncology. 2005 76:S64-S65
  • *Patel, S, Gilbert, L, Schwartz, M, Portelance, L, Stanimir, G, Souhami, L. Predictors of outcome and patterns of failure in patients with pathologic stage III endometrial cancer confined to the pelvis, International Journal of Radiation Oncology Biology Physics 2005, 63(2):S212. DOI: 10.1016/j.ijrobp.2005.07.365
  • Mayrand MH, Duarte-Franco E, Coutlée F, Rodrigues I, Walter SD Ratnam S, Franco EL. CCCaST Study Group. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: Design, methods and preliminary accrual results of the Canadian Cervical Cancer Screening Trial (CCCaST). International Journal of Cancer, 2006; 119(3): 615-623 (authorship within the CCCaST Study Group as L Gilbert).
  • *Niazi TM, Souhami L, Portelance L, Bahoric B, Gilbert L, Stanimir G. Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1108-1113. doi: 10.1016/j.ijrobp.2005.04.036 PMID: 16099598
  • *Patel, S, Tan, L, Gilbert, L, Portelance, L, Stanimir G, Souhami, L. Adjuvant radiotherapy improves outcome in pathologic stage III endometrial cancer confined to the pelvis, Ejc Supplements 2005, 3(2):268.
  • *Gilbert RM, Tan L, Kerim-Dekeni A, Gillett PG, Souhami L, Portelance L, Patel L, Gilbert L. Endometrial cancers in women under 40 years. Insights from the McGill Experience. International Journal of Gynecological Cancer, 2005; 15(Suppl.2):99.
  • *Rao GD, Chian RC, Son WS, Gilbert L, Tan SL. Fertility preservation in women undergoing cancer treatment. The Lancet, 2004; 363:1829-1830. DOI: 10.1016/S0140-6736(04)16320-4
  • Souhami, L, Patel, S, Portelance L, Stanimir, G, Gilbert, L. Analysis of predictors of toxicity in patients with stage III endometrial cancer confined to the pelvis treated with external-beam radiotherapy, Ejc Supplements 2005;3(2):207.
  • Foulkes WD, Narod SA, Swenerton K, Panabaker K, Gilbert L. Re: Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. Journal of the National Cancer Institute, 2003; 95(21):1640. DOI: 10.1093/jnci/djg102
  • Gilbert L, Krishnamurthy S, Tan SL, Franco EL. Estrogen Replacement and the risk of Ovarian Cancer international journal of gynecological cancer in Postmenopausal Women. Journal of the American Medical Association, 2002; 288:2538-2539.
  • Gilbert L, Nicholl J, Alex S, et al. Ethnic differences in the outcome of serum screening for Down’s syndrome. British Medical Journal, January 1996; 312:94-95.
  • Gilbert L, Nicholl J, Mander A. Assay used in serum screening for Downs’s syndrome may depend on ethnic make-up of population. British Medical Journal, 1996; 313:297. (Letter to the Editor)
  • Pierce LJ, Merino MJ, D’Angelo T, Barker EA, Gilbert L, Cowan KH, Steinberg SM, Glatstein E. Is c-erb B-2 a predictor for recurrent disease in early stage breast cancer? Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):395-403. PMID: 7903962
  • Gilbert L, Elwood LJ, Merino M, Masood S, Barnes R, Steinberg SM, Lazarous D, Pierce L, d’Angelo T, Moscow JA, Townsend AJ, Cowan KH. A Pilot Study of Pi-Class Glutathione S-Transferase Expression in Breast Cancer: Correlation with Estrogen Receptor Expression and Prognosis in Node-Negative Breast Cancer. Journal of Clinical Oncology, January 1993; 11(1):49-58.
  • Gilbert L, Masood S, Barnes R, Elwood L, Merino M, Lazarous D, Cowan KH. The Relationship Between Glutathione-S-Transferase Expression and Estrogen and Progesterone-Receptor Status in Breast Cancer by Immunocytochemical Assay, Laboratory Investigation 1991; 64 (1):A11.
  • Saunders N, Anderson D, Gilbert L, Sharp F. Unsatisfactory colposcopy and the response to orally administered oestrogen: a randomised double blind placebo controlled trial. British Journal of Obstetrics and Gynaecology, August 1990; 97(8): 731-733. DOI: 10.1111/j.1471-0528.1990.tb16248.x
  • Gilbert L, Saunders N, Sharp F. Microcolpohysteroscopic tailoring of knife cone biopsies. Obstetrics and Gynaecology, July 1990; 76(l):101-105.
  • Saunders N, Anderson D, Sheridan E, Gilbert L, Sharp F. Endoscopic localisation of the squamo-columnar junction prior to cold knife conization of the cervix – Experience of 284 patients. Cancer, March 1990; 60(6):1312-1317. doi: 10.1002/1097-0142(19900315)65:6<1312::AID-CNCR2820650610>3.0.CO;2-1
  • Saunders NJS, Spiby H, Gilbert L, Fraser R, Mutton P, Hall J, Jackson A, Edmonds D. Oxytocin infusion during second stage of labour in primiparous women using epidural analgesia: a randomised double blind placebo controlled trial. British Medical Journal, December 1989; 299:1423-1446.
  • Gilbert L, Saunders N, Stringer R, Sharp F. Haemostasis and Knife Cone Biopsy: A Prospective Randomized Trial Comparing a Suture versus Non-Suture Technique. Obstetrics and Gynaecology, October 1989; 74:640-643.
  • Gilbert L, Saunders N, Sharp F. The management of multiple pregnancies in women with a lower uterine segment scar. Is a caesarean section really the safe option? British Journal of Obstetrics and Gynaecology, December 1988; 95:1312-1316. DOI: 10.1111/j.1471-0528.1988.tb06824.x
  • Saunders NJ, Gilbert L, Sharp F. A Randomized Prospective-Study of Suturing Versus Packing of the Cone Bed After Knife Cone Biopsy, Colposcopy & Gynecologic Laser Surgery 1987;3 (4): 232.
  • Gilbert L, Porter W, Brown V. Postpartum Haemorrhage – a continuing problem. British Journal of Obstetrics and Gynaecology, January 1987; 94:67-71 https://doi.org/10.1111/j.1471-0528.1987.tb02255.x

Other Publications

  • Non-Peer Reviewed:

    • Ido Laskov, Nadav Michaan, Liron Kogan, Xing Zeng, Shannon Salvador, Kris Jardon, Susie Lau, Lucy Gilbert, Walter H Gotlieb, Roy Kessous. The Impact of Intra-Uterine Manipulators on Outcome and Recurrence Patterns of Endometrial Cancer Patients Undergoing Minimally Invasive Surgery, Research Square, June 24, 2021 https//doi.org/10.21203/rs.3.rs-538902/v1
  • Reviews:
    • Gilbert L, Piedimonte S. Hormone Replacement Therapy and Malignancies (review). The Canadian Journal of Diagnosis, (27)12: 58-62, December 2010
    • Gilbert L. HRT and Alternatives: A “Natural” Choice? Canadian Journal of CME, 2005; 17(12): 86-89
    • Gilbert L. Human Papilloma virus – Are its days numbered? Parkhurst Exchange, 2003; 13(11)
  • Book Chapters:
    • Ahmed Nazer Lucy Gilbert, A. El-Messdi. Chapter 72: Adenexal Mass in Pregnancy, OSCES Obs & Maternal Fetal Medicine, McGill University, November 3, 2020
    • Gynecological cancers: Cervical, Endometrial and Ovarian Cancers Module 13, Oncology for Practicing Physicians, McGill Accreditation, Program Development and Program Revision, 2015
    • Gynecological cancers in Oncology Module Sponsored by the Canadian Council of Pharmaceutical Education) in partnership with the Continuing Health Professional Education office at McGill University
    • In-vitro maturation and oocyte vitrification for the treatment of infertility and the preservation of fertility. Tan S L, Huang, JYJ, Baris A, Chian, Ri-Cheng; Hananel H; Demirtas E, Gilbert L. In Reproductive Medicine and Surgery, Pages: 33-36, Published: 2009. Editor(s): Dubuisson, JB; Gomel, V. Publishers: Medimond S R L Via Maserati 5, Italy
    • Content-Based Retrieval and Classification of Ultrasound Medical Images of Ovarian Cysts. Sohail AS, Bhattacharya P, Mudur SP, Krishnamurthy S, Gilbert L. Book Title: Artificial Neural Networks in Pattern Recognition. Lecture Notes in Computer Science. Volume 5998, 2010, pp 173-184. Editors: F Schwenker & N El Gayar,. Publisher Springer Berlin Heidelberg
    • *Controversies regarding the utility of lymphadenectomy in endometrial cancer. Frederik Peeters, Lucy Gilbert; Book title: Cancer of the Uterine Endometrium – Advances and Controversies-Publisher: InTech Published: February 29, 2012, doi:10.5772/25584.

Recent Abstracts & Presentations

  • Venkatesh Krishnan, Ching-Wei Chang, Elyssa Badr, Ritu Salani, Bradley J Monk, Yong-Man Kim, Sharad Ghamande, Shaundra L Hall, Domenica Lorusso, Lisa Barraclough, Lucy Gilbert, Adrian Guzman Ramirez, Chien-Hsing Lu, Dominique Berton, Nicoletta Colombo, Marcela Castro, Yvonne G Lin, Mary McCormack, Luciana Molinero. Tumor Microenvironment (TME) biomarkers of TIGIT and PD-L1 immne checkpoint blockade in Cervical Cancer: SKYSCRAPER-04(SKY04) Sub-Study, AACR Annual Meeting, San Diego, California, April 5-10, 2024 [submitted abstract]

  • Joyce Li, Basile Tessier-Cloutier, Areej Al Khatib, Thomth/e Revil, Lawrie Shahbazian, Dong Bach Hguyen, Shuk On Annie Leung, Lucy Gilbert, Andrew Zakhari. Mutational profiling of benign endometrial tissue may predict the presence of endometriosis, USCAP 113th Annual Meeting, Baltimore MD, March 23 – 28, 2024 (Submitted Abstract 1244)
  • Sedighe Esmaeilzade, Vish Tummala, Shuk On Annie Leung, Xing Ziggy Zeng, Victoria Aspasia Mandilaras, Joanne Alfieri, Daniella Joseph Pillai, Fadi Wardeh, Areej Alkhati, Vishaal Gupta, Christopher Zuraik, Lawrie Shahbazian, John Sampalis, Lucy Gilbert. Aduvant Treatment in High Grade Serous Endometrial Carcinoma: A Comprehensive Insitutional Review, CCRC, Halifax, NS., Nov 12-14, 2023 – oral presentation
  • Ritu Salani, Bradley Monk, Yong-Man Kim, Sharad Ghamande, Shaundra Hall, Domenica Lorusso, Lisa Barraclough, Lucy Gilbert, Adian Guzman Ramirez, Lu Chien Hsing, Dominique Berton, Nicoletta Colombo, Youyou Hu, Venkatesh Krishnan, Yuning Feng, Nicole Kim, Marcela Castro, Yvonne G Lin, Mary McCormack. Efficacy and safety results from SKYSCRAPER-04: An open-label randomized phase 2 metastatic/recurrent cervical cancer, IGCS, Seoul, Korea, Nov 5-7, 2023 (to be submitted)
  • Zoltan Novak, Michael A Gold, Jorn Herrstedt, Sarah Gill, Antonella Savarese, John P Diaz, Stefan Kommoss, Guilherme Cantuaria, Ingrid Boere, Evelyn Fleming, Lucy Gilbert, Kathryn Pennington, Roert Holloway, Eirwen M Miller, Rachel Miller, Matthew Powell, Christine Dabrowski, Shadi Stevens, Mansoor Raz Mira, Carolyne McCourt. Management of Immune-Related Adverse Events in Patients with Primary Advanced or Recurrent Endometrial Cancer: Dostarlimab plus Chemotherapy Compared with Chemotherapy Alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial, IGCS 5th Global Meeting, November 5-7, 2023, Seoul, Korea – poster
  • Ira Winer, Ulka N Vaishampayan, Lucy Gilbert, Seth D Rosen, Shipra Gandhi, Vamsidhar Velcheti, Rita Dalal, Yangchun Du, Sarah Donatelli, Sonali Panchabhai, James F Strauss, Sarina A Piha-Paul. Prelininary Pharmacodynamic Characterization In Patients with Platinum-Resistant Ovarian Cancer Treated with Nemvaleukin in Combination with Pembrolizumab, AACR Special Conference in Cancer Research Meeting, Boston, MA.,October 5-7, 2023
  • Dana Chase, Line Bjorge, Robert Coleman, Olekdanr Zub, Eirwen Miller, Robert Angioli, Cara Mathews, Lars C Hanker, Michael G Teneriello, Anna Reyners, Matthew Powell, Lucy Gibert, Noelle Cloven, Sarah Gill, Bradley J Monk, Bhavana Pothuri, Jamie Garside, Odette Allonby, Carolyn McCourt, Mansoor Raza Mirza. Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel vuersus carboplatin-paclitaxel in the ENGOT-EN6/GOG-3031/RUBY trial, 24th ESGO, Istabul, Turkiye, September 28-October 1, 2023 (oral presentation)
  • Annika Auranen, Destin Black, Vladyslav Sukhin, Sudarshan Sharma, Graziana Ronzino, Lisa M Landrum, Dirk Bauerschlag, Lyndsay Willmott, Roy Lalisang, Joseph Buscema, Lucy Gilbert, Robert L Coleman, David Bender, Amy Arnstrong, Nicole Nevadunsky, Matthew A Powell, Christine Dabrowski, Shadi Stevens, Mansoor Raza Mirza, Evelyne Fleming. Safety of Dostarlimab in Combination with Chemotherapy win Patitnes with Primary Advance or Re3current Endomtral Cancer in a Phase 3 Randomzed, Placebo-Controlled Trial (ENGOT-EN6-NSGO/GOG-3031/Ruby), ESGO, Istanbul, Turkiye, September 28 – October 1, 2023 – oral presentation
  • Brian Slomovitz, Nicoline Raaschou-Jensen, Robert L Coleman, Lucy Gilbert, Matthew A Powell, David Cibula, Sharad Ghamande, Laura Zavallone, Alberto Mendivil, Beyhan Ataseven, Destin Black, Machteld Wymenga, Caroline Billingsley, Lyndsay Willmott, Carolyne McGourt Iwona Podzielinski, Orlando Doehring, Jamie Garside, Thomas J Herzog, Mansoor Raza Mirza. PFS2 and Adjustment of Overall Survival for Subsequent Anticancer Therapy in Patients with Primary Advanced or Recurrent Endometrial Cancer Treated with Dostarlimab plus Chemotherapy or Chemotherapy Alone in theENGOT-EN3-NSGO/GOG-3031/Ruby Trial, ESMO, Madrid, Spain October 20-24, 2023 – Poster Submission
  • Mansoor Rza Mirza, Sudarshan Shama, Jorn Herrstedt, Mark S Shahin, David Cibula, Evelyn Flemming, Francesco Raspagliesi, Joseph Buscema, Lars C Hanker, Robert L Coleman, Ingrid Boere, Kellie Shcnider, Lucy Gilbert, Brian Slomovit, Michael G Teneriello, Matthew A Powel, Srimoyee Ghosh, Shadi Stevens, Kari Ring, Asley Stuckey. Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cacer (pA/rEC): Analysis of progression free survival and overall survival outcomes by the molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial, ESMO, Madrid, Spain, Oct 20-24, 2023 – oral presentation (Submitted)
  • Areej Al Khatib, Timothee Revil, Lucy Gilbert, Basile Tessier-Cloutier. Mutational profiling of recurrent endometrial endometroid carcinoma No specific molecular profile (NSMP)/p5f3wt using endometrial brush sampling, #5th European Congress of Pathology, Dublin, Ireland September 9-13, 2023 – Oral Presentation
  • Florentin Racovitan, Areej Al Khatib, Vish Tummala, Lawrie Shahbazian, Victoria Mandilaras, Xing Zeng, Lucy Gilbert. Prognostic value of isolated Tumor Cells in early-stage, low grade endometrial cancer patients, Obstetrics & Gynecology Research Day 2023, McGill Symposium on Women’s Health, Montreal, Sept 7, 2023 – e-poster
  • Eman Soliman, Florentin Racovitan, Areej Al Khatib, Vish Tummala, Lawrie Shabazian, Xing Zeng, Annie Leung, Lucy Gilbert, Victoria Mandilaras. Effect of Bevacizumab treatment in ovarian cancer patients presenting with ascites or pleural effusion of the frequency of interventions (paracentesis or thoracentesis), Obstetrics & Gynecology Research Day 2023, McGill Symposium on Women’s Health, Montreal, Sept 7, 2023 – e-poster
  • Daniella Joseph Pillai, Deepinder Kaur Sohi, Florentin Racovitan, Areej Khatib, Xing Zeng, Annie Leung, Victoria Mandilaras, Fadi Wardeh, Sedighe Esmaelizade, Lawrie Shahbazian, Lucy Gilbert. Obstetrics & Gynecology Research Day 2023, McGill Symposium on Women’s Health, Montreal, Sept 7, 2023 – e-poster
  • Tracy Nami, Florentin Racovitan, Areej J Al Khatib, Vish Tummala, Lawrie Shahbazian, Xing Zeng, Victoria Mandilaras, Lucy Gilbert, Annie Leung. Comparing outcomes between Primary Ovarian Carcinoma and Synchronous Ovarian and Endometrial Carcimona, Obstetrics & Gynecology Research Day 2023, McGill Symposium on Women’s Health, Montreal, Sept 7, 2023 – e-poster
  • Matthew A. Powell, Sakari Hietanen, Robert L Colman, Bradley J. Monk, Oleksandr Zub, David M. O’Malley, Lucy Gilbert, Iwona Podzielinski, Roberto Angioli, Dana Chase, Dirk Bauerschlag, Destin Black, Annemarie Thijs, Sudarshan Sharma, Michael A. Gold, Kari L Ring, Zangdong He, Shadi Stevens, Brian Slomovitz, Mansoor R. Mirza. Dostarlimab for primary advanced or recurrent endometrial cancer: Outcomes by blinded independent central review of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY), ASCO, Chicago, IL., June 2-6, 2023
    • Encore presentation, Clinical Oncology Society of Australia (COSA) November 1-3, Melbourne Australia – poster presentation by Ashish Banerjee
  • Lisa Marie Barroilhet, Myong Cheol Lim, Sunil Gupta, Srinivas Rao Jada, Jung-Yun Lee, Lucy Gilbert, Babak Edraki, Casey Cosgrove, Joyce N. Barlin, Diane M. Provencher, Lukas Rob, Devansu Tewari, David M. O’Malley, Angeles Alvarez Secord. Flora-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC): Phase III, double blind, placebo controlled, global, multinational study. ASCO, Chicago, IL., June 2-6, 2023 (submitted abstract 423084)
  • Mansoor Raza Mirza, Matthew A. Powell, Caroline Lundgren, Vladyslav Sukhin, Bhavana Pothuri, Lucy Gilbert, Sarah Gill, Graziana Ronzino, Nicole Nevadunsky, Stefan Kommoss, Lyndsay Willmott, Ingrid Boere, Cara Amanda Mathews, Joseph Buscema, Michael G. Teneriello, Mark S. Shahin, Oren Meyers, Jamie Garside, Robert L. Coleman, Brian M. Slomovitz. Patient-reported outcomes in primary advanced or recurrent endometrial cancer for patients treated with dostarlimab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel in the ENGOT-EN6/GOG3031/RUBY trial, ASCO, Chicago, IL., June 2-6, 2023 (submitted abstract 421220)
    • Adaptive Encore, Academy of Oncology Nurse and Patient Navigators (AONN) 14th Annual Conference 2023, Nov 15-19, San Antonio, Texas, US (poster presentation by Michelle McClosky
    • Updated Encore presented at the ASCO Quality Care Symposium, Boston, Massachusetts, October 27-28, 2023 – poster presentation
  • Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny, Susana N. Banerjee, Sandro Pignata, Nicoletta Colombo, John Maroney, Casey Cosgrove, Jung-Yun Lee, Jacqueline Maria Tromp, Lucy Gilbert, Diana Bello-Roufai, Joseph Buscema, Rowan Miller, Tashanna K. N. Myers, Michael W. Method, Domenica Lorusso, Renaud Sabatier, Toon Van Gorp; Stephenson. Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression, ASCO, Chicago, IL., June 2-6, 2023 (submitted abstract 417460)
  • Mansoor R Mirza, Dana Chase, Brian Slomovitz, René DePont Christensen, Zoltá Novák, Destin Black, Lucy Gilbert, Sudarshan Sharma, Giorgio Valabrega, Lisa M. Landrum, Lars C Hanker, Ashley Stuckey, Ingrid Boere, Michael A Gold, Sarah E Gill, Bradley J Monk, Zandong He, Shadi Stevens, Robert L Coleman, Mathew A Powell. Dostarlimab in Combination with Chemotherapy for the Treatment of Advanced or Recurrent Endometrial Cancer: A Placebo-Controlled Randomized Phase 3 Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY), ESMO Virtual Plenary 2023 March 25-28, 2023
  • Lars C Hanker, Florian Hetiz, Dominik Denschlag, Manssor R Mirza, Dana Chase, Brian Slomovitz, René dePont Christensen, Zoltan Novak, Destin Black, Lucy Gilbert, Sudarshan Sharma, Girogio Valabrega, Lis M Landrun Ashley Stuckey, Ingrid Boere, Michael A Gold, Sarah E Gill, Bardley J Monk, Zangdong He, Shadi Stevens, Robert L Colemam, Matthew A Power., Deutscher Krebskongress 36th Annual German Cancer C ongress DK, Februay 21-24, 2024
  • Esmo Virtual Plenary with ACCR Expert Commentary, ESMO Annual 2023, Oct 20 – 24, 2023, Madrid Spain
  • Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, Jubilee Brown, Sharad Ghamande, Cara Mathews, David M. O’Malley, Valentina Boni, Adiano Gravina, Susana Banerjee, Rowan E. Miller, Joanna Pikiel, Mansoor R. Mirza, Tao Duan, Xinwi Han, Sybil Zildjian, Elfetherios Zografos, Jennifer Veneris, Anna B. Tinker. Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: a post hoc analysis of the GARNET study –submitted upon invitation to European Medical Journal (EMJ) Oncology
  • Lucy Gilbert, Ana Oaknin, Ursula A. Malulonis, Gina M. Mantia-Smaldone, Peter C. Lim, Cesar M. Castro, Diane Provencher, Sanaz Memarzadeh, Michael Method, Jiuzhou Wang, Kathleen N. Moore, David O’Malley. Saftey and efficacy of mirvetuximab soravtansine, a folate recptor alph (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer, to be submitted to Journal of Gynecologic Oncology
  • Florian Stehlin, Deepinder Sohi, Lucy Gilbert, Ghislaine Annie Clarisse Isabwe. Hypersensitivity Reactions to Paclitaxel: Premedicaion Enhancemnt to Safely Achieve Treatment Completion, AAAAI 2023 Annual Meeting, San Antoinio, Texas, February 24-27, 2023., Journal of Allergy and Clinical Immunology February 2023 online supplement – Poster Presentation
  • Lucy Gilbert, Kathleen N. Moore, Vanessa Samouëlian, Cara Mathews, Maria Pilar Barretina-Ginesta, Janet S Rador, Anna V. Tinker, Adriano Gravina, Joanna Pikiel, Grace Antony, Elfetherios Zografos, Jennifer Veneris, Ana Oaknin. Impact of duration of treatment on efficacy outcomes: A post-hoc analysis of the GARNET endometrial cancer cohorts, Society for Immunotherapy of Cancer, Boston Mass., November 8-12, 2022 – Oral Presentation
  • Oaknin A, Pothuri, Gilbert L, Sabatier R, Brown J, Ghamande S, Mathews C, O’Malley D, Boni V, Gravina A, Banerjee S, Miller R, Pikiel J, Mirza MR, Dewal N, Antony G, Zografos E, Veneris J, Tinker A. A Subgroup analysis of response rate by patient characteristics and biomarkers in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET study, SGO, Tampa Florida, Mar 25-28, 2023 ( submitted)
  • Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, Jubilee Brown, Sharad Ghamande, Cara Mathews, David M. O’Malley, Rebecca Kristeleit, Valentina Boni, Adriano Gravina, Susana Banerjee, Rowan E. Miller, Joanna Pikiel, Mansoor R Mirza, Tao Duan, Yuping Dong, Elftherios Zografos, Jennier Veneris, Anna Tinker. A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy Dostarlimab in the GARNET Trial, ESGO 2022, Berlin, Germany, Oct 27-30, 2022
    • Encore presentation SGO 54th Annual Meeting, Tampa, FL., March 25-28, 2023
  • David O’Malley, Ana Oaknin, Ursula Matulonis, Gina Mantia-Smaldone, Peter Lim, Cesar M Castro, Diane Provencher, Sanaz Memarzadeh, Michael Method, Jiuzhou Wang, Brooke Esteve, Kathleen Moore, Lucy Gilbert. Mirevtuximab Soravtansine and Bevacizumab in Folate receptor Alpha-Positive Ovarian Cancer: Efficacy in patients with and without prior Bevacizumab , IGCS Annual Global Meeting, New York City, NY, September 29 – Oct 1, 2022– Oral Plenary
  • Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S, Mathews C, O’Malley D, Boni V, Gravina A, Banjeree S, miller R, Pikiel J, Mirza M, Duan T, Sildjian S, Stari A, Zografos E, Veneris J, Tinker A. Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study, IGCS 4th Global Meeting, New York, New York Sep 29 – Oct 1 – poster presentation
    • Encore presentation: ESGO 23rd International Meeting, Oct 27 – 30, Berlin Germany
  • Anna V. Tinker, Renaud Sabatier, Adriano Gravina, Lucy Gilbert, Jubilee Brown, Vanessa Samoulian, Clare Reade, Cara Mathews, Susan Ellard, Susana Banerjee, Maria Pilar Barretina-Ginesta, Rowan Miller, Charles Leath, Bhavana Pothuri, Tao Duan,, Zinwei Han, Elftherios Zografos, Jennifer Veneris, Ana Oaknin. Post-hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with Dostarlimab, IGCS 4th Annual Global Meeting, New York City, September 29-Oct 1, 2022 – Accepted oral presentation
    • Encore presentation: HOPA, Phoenix, AZ mar 29-April 1, 2023
    • Encore presentation: ESGO 2022– 23rd International Meeting, Oct 27 – 30, Berlin, Germany
  • Wilson H. Miller, Jr., Anthony Shields, Diane Provencher, Lucy Gilbert, Geoffrey Shapiro, Amit Oza, Jennifer Spratlin, Stephanie Lheureux, Gita Bhat, Shannon Salvador, Paulo Nunes, Susie Lau, Ira Winer, Jennifer Keene, Sara Zaknoen, Patricia Smith, Inger Darling, John Polzer, Jonh R Stille, Caroline Fortier, Darcy Vincett, and Quincy Chu. A Phase 1b Study of Oral Chk1 Inhibitor LY2880070 in Combination with Low-Dose Gemcitabine in Patients with Advanced Ovarian Cancer, ESMO, Paris France, Sept 9-13, 2022 – poster presentation
  • Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, Jubilee Brown, Sharad Ghamande, Cara Mathews, David M. O’Malley, Valentina Boni, Adriano Gravina, Susana Banerjee, Rowan E. Miller, Joanne Pikiel, Mansour R. Mirza, Tao Duan, Xinwei Han, Grace Antony, Sybil Zildjian, Elfetherios Zografos, Jennifer Veneris, Anna V Tinker. Progression-free Survival (PFS) and Overall Survival (OS) in Advanced/Recurrent (AR) Mismatch Repair Deficient/Microsatellite Instability-High or Proficient/Stable (dMMR/MSI-H or MMRp/MSS) Endometrial Cancer (EC) Treated with Dostarlimab in the Garnet Study, ESMO, Paris France, Sept 9-13, 2022 – poster presentation
  • Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, Jubilee Brown, Sharad Ghamande, Cara Mathews, David M. O’Malley, Valentina Boni, Adriano Gravina, Susana Banerjee, Rowan E. Miller, Joanne Pikiel, Mansour R. Mirza, Tao Duan, Xinwei Han, Sybil Zildjian, Jennifer Veneris, Anna V Tinker. Efficacy of Dostarlimab in Endometrial Cancer (EC) by Molecular Subtype: A Post Hoc Analysis of the Garnet Study, EMSO, Paris, France, Sept 9 – 13, 2022- poster presentation
    • Encore presentation to 23rd Internal Meeting of the ESGO, Berlin, Germany, Oct 27-30, 2022
  • Gupta V, Drolet A-R, Matanes E, Power J, Suarthana E, Gilbert L, Leung SOA, Zeng X. Comparing Thoracic Epidural Analgesia To Surgeo-Administered Continuos Transversus Abdominus Plane Blocks in Gyaecologic Oncology patients: A Retrospective Cohort Study, 43rd GOC Annual Meeting, June 10, 2022 (virtual)
    • Encore presentation ESGO, Berlin, Germany October 27-30, 2022
  • Ana Oaknin, Lucy Gilbert, Anna V Tinker, Jubilee Brown, Cara Mathews, Joshual Press, Renaud Sabatier, David O’Malley, Vanessa Samouëlian, Min-Ji Bae, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatgae, Rebecca Kristeleit, Charles Leath III, Jennifer Veneris, Tao Duan, Ellie Im, Bhavana Pothuri. Dostalimab in advanced/recurrent mismatch repair deficient/microsatellite instability high or proficient/stable endometrial cancer: the GARNET study, ASCO 58th Annual Meeting, Chicago, Il and virtual, Jun 3-7, 2022
    • Encore presentation: 2nd International Congress AOS & 48th Annual Meeting KCA, June 16 – 18, 2022
    • Encore presentation: CSCO 25th Annual Meeting, Siamen, China and virtual, Sept 21-25, 2022
    • Encore presentation: Clinical Oncology Society of Australia (COSA), 49th Annual Scientific Meeting, November 2-4, 2022
  • Angeles Alvarez Secord, Lisa Marie Barroilhet, Myong Cheol Lim, Sunil Gupta, Sonia Oosman, Jada Srinivas Rao, John O. Schorge, Joyce N. Barlin, Lucy Gilbert, Devansu Tewari, Michael Gold, Diane M. Provencher, Jung-Yun Lee, Kristin Leigh Bixel, Eduardo Yanez, Lukas Rob, David M. O’Malley. FLORA-5/GOG3035: Front-line Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab [PCO]) vs Chemotherapy (Paclitaxel-Carboplatin-Placebo [PCP]) in Patients with Advanced Epithelial Ovarian Cancer (EOC): Phase III Double Blind Placebo Controlled Global, Multinational Study, ASCO Annual Meeting 2022, June 3-7, McCormick Place, Chicago, Il Abstract 375608 [submitted]
  • Brian Slomovitz, David Cibula, Cagatay Taskiran, Mansoor Raza Mirza, Beata Maćkowiak-Matejczk, Emma Hudson, Ignacio Romero, Nicoletta Columbo, Jacob Korach, Rutie Yin, Lucy Gilbert, Kosei Hasegawaa, Alexandra Tyulyandina Sergeevna, Sally Baron-Hay, Lyndsay Willmott, Floor Backes, Robert J. Orlwoski, Xuan Zhou, Vivek, Khemka, Sando Pignata. KEYNOTE-C93/GOG-3064/ENGOT-en15: A Phase 3, randomized, open-label study of first –line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma, ASCO Annual Meeting 2022, June 3-7, McCormick Place, Chicago, Il Abstract 371882 – Poster Presentation [TPS5623 – Publication number]
    • Updated Encore presentation: Submitted to ANZGOG’s Annual Scientific Meeting, Brisbane, March 22-24, 2023
    • Encore presentation: Brian Slomovitz, David Cibula, Mtuat Gultekin, Mansoor Raza Mirza, Beata Mackowiak-Matejczyk, Alexandra Taylor, Ignacio Romero, Nicoletta Colombo, Jacob Korach, Jianqing Zhu, Lucy Gilbert, Kosei Hasegawa, Jae-Weon Kim, Sally Baron-Hay, Vicky Makker, Robert L Coleman, Robert J. Orlowski, Xuan Zhou, Vivek Khemla, Sandro Pgnata. IGCS Annual Global Meeting, Sep 29-Oct 1, 2022 – poster presentationa
  • Ying L. Liu, Cara Amanda Mathews, Fiona Simpkins, Karen Anne Cadoo, Diane M. Provencher, Colleen McCormick, Adam EI Nagger, Alon D. Altman, Lucy Gilbert, Destin Black, Nashwa Kabil, Rosemary Taylor, Alan Barnicle, Jiefen Munley, Carol Aghajanian. Oliparib treatment (tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: characterization of pts with long-term (LT) and short-term (ST) Treatment duration in LIGHT, ASCO Annual Meeting 2022, June 3-7, McCormick Place, Chicago, Il Abstract 367100 [submitted]
    • Encore presentation: IGCS Annual Global meeting, New York City, September 29 – October 1, 2022
  • Lucy Gilbert, Ana Oaknin, Anna V. Tinker, Jubilee Brown, Cara Mathews, Joshua Press, Renaud Sabatier, David M. O’Malley, Vanessa Samouliën, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatage, Rebecca Kristeliet, Charles Leath III, Jennier Veneris, Tao Duan, Ellie Im, Bhavan Potri. Dostarlimab in Advanced, Rucurrent Mismatch Repair Deficient/Microsatellite Instability High or Profcient/Stable Endometrial Cancer: The Garnet Study, Canadian Association of Pharmacy in Oncology (CAPhO) 2022, Virtuel Conference, April 21-24, 2022
  • Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, Sharad A. Ghamande, Adriano Gravina, Emiliano Calvo, Susana N. Banerjee, Rowan Miller, Joanna Pikiel, Mansoor R. Mirza, Tao Duan, Sybil Zildjian, Eleftherios Zografos, Jennifer Taylor Veneris, Anna Tinker. Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/sable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study, ASCO Annual Meeting 2022, June 3-7, McCormick Place, Chicago, Il Abstract 365954
    • Oral Communication in the Clinical Science Symposium/Molecular-Based Treatment for Endometrial Cancer
    • Encore presentation 2nd International Congress AOS & 48th Annual Meeting KCA, June, CAPhO 16-18, 2022
  • Ulka N. Vaishampayan, Piotr Tomczak, Jameel Muzaffar, Ira Seth Winer, Seth David Rosen, Christopher J. Hoimes, Aman Chauhan, Anna Spreafico, Karl D. Lewis, Debora S. Bruno. Oliver Dumas, David F. McDermott, James Fredric Strauss, Quincy S. Chu, Lucy Gilbert, Arvind Chaudhry, Julie R. Graham, Valentina Boni, Marc S. Ernstoff, Vamsidhar Velcheti. Nemvaleukin alfa (nemvaleukin, ALKS 4230) monotherapy and in combination with pembrolizumab in patients (Pts) with advanced solid tumors: ARTISTRY-1 primary analysis, ASCO Annual Meeting 2022, June 3-7, McCormick Place, Chicago, Il Abstract 364046 [submitted]
    • Encore presentation, ESMO ASIA 2022, Singapore, Dec 2-4, 2022
    • Encore presentation, 15th Annual Korean Society of Medical Oncology, Seoul, Korea Sep 1-2, 2022
    • Encore presentation from KSMO, Society for Melanoma Research – 19th International Melanoma Research Congress. Oct 17-20, 2022, Edinburgh UK
    • Encore presentation to the 25th Annual Chinese Society of Clinical Oncology, Xiamen, China, Sept 21 – 25, 2022
    • Encore presentation to ESGO 23rd International Meeting, Berlin, Germany, Oct 27-30, 2022
  • Thierry André, Susana Banerjee, Dominique Berton, Susan L. Ellard, Begona Jimenez, Vanessa Samouëlien, Lucy Gilbert, Valentina Boni, Xinwei Han, Grace Antony, Jennifer Verneris, Ana Oaknin. Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial, AACR Annual Meeting, New Orleans, Louisiana, April 8-13, 2022
    • Encore presentation at the 35th German Cancer Congress, November 13- 16, 2022 – presented by Arndt Vogel
    • Encore presentation at the European Society of Gynaecological Oncology – 23rd International Meeting, Oct 27 – 30, 2022, Berlin, Germany
    • Encore presentation at the Heartland Association for Gynecologic Oncology, 3rd Annual Meeting, September 29 – Oct 1, 2022, Ann Arbor, Michigan
  • Lucy Gilbert, Ana Oaknin, Anna V Tinker, Jubilee Brown, Cara Mathews, Joshual Press, Renaud Sabatier, David O’Malley, Vanessa Samouëlian, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatgae, Rebecca Kristeleit, Charles Leath III, Jennifer Veneris, Tao Duan, Ellie Im, Bhavana Pothuri. Dostalimab in advanced/recurrent mismatch repair deficient/microsatellite instability high or proficient/stable endometrial cancer: the GARNET study, CaPhO 2022 Virtual Conference, April 21 – 24, 2022 – Encore presentation by Lucy Gilbert
  • Ira Winer, Ulka N. Vaishampayan Lucy Gilbert, Seth D. Rosen, Shipra Ghandi, Yan Wang, Yangchun Du, Lei Sun, Rita Dalal, Monali Desai, Julie R. Graham, Vamsidhar Velcheti, James Strauss. Clinical outcomes of ovarian cancer patients treated with the novel engineered cytokine nemvaleukin alfa in combination with the PD-1 inhibitor pembrolizumab: recent data from Artistry -1, 53rd Annual Meeting on Women’s Cancer (SGO) Phoenix, AZ March 19-22, 2022 Accepted Oral Presentation
  • Thomas J. Herzog, Kathleen Moore, Panagiotis A. Konstantinopoulos, Lucy Gilbert, John L. Hays, Bradley Monk, David M. O’Malley, Rita Dalal, Julie R. Graham, Monali Desai, Yan Wang, Lei Sun, Robert L. Coleman. ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa, a novel engineered cytokine, in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, Society for Gynecologic Oncology (SGO) Phoenix, AZ, March 18-20, 2022 – Poster Presentation, Journal of Clinical Oncology 40(16) suppl., https://ascopubs.org/doi/abs/10.1200/JCO.2022.4016_supple.TPS5609
    • Encore presentation, CSCO 2023, Xiamen City, Fujian, China, Sept 21-25
    • Encore presentation, KSMO 2023, Seoul, Korea, Sep 7-8, 2023 ( to be submitted)
    • Encore presentation, ASCO, Chicago Il, June 2-6, 2023 (abstract 399442)
    • Encore presentation, 12th Annual International Charité Mayo Conference, Berlin, Germany, April 26-29, 2023
    • Encore presentation, Society for Gynecologic Oncology (SGO), March 25-28, 2023, Tampa Florida (submitted)
    • Encore presentation ESGO 23rd International Meeting, Berlin, Germany, October 27 – 30
    • Encore presentation, CSCO 25th Annual Meeting, Xiamen, China, September 21-25, 2022 – Oral presentation
    • Encore presentation: KSMO 2022, Seoul, Korea, Sept 1 – 2, 2022
    • Encore presentation, ASCO 58th Annual Meeting 2022, June 3-7, McCormick Place, Chicago, Il, Abstract 346150
  • Ana Oaknin, Lucy Gilbert, Anna V. Tinker, Renaud Sabatier, Jubilee Brown, Cara Mathews, Valentina Boni , Vanessa Samouëlian, David M. O’Malley, Andrea Jewell, Susana Banerjee, Grace Antony, Jennifer Veneris, Bhavana Pothuri. Antitumor Activity and Safety of Dostarlimab Therapy in Patients with Endometrial Cancer by Age Subgroups: a Post Hoc Analysis from the Garnet Trial, 53rd Annual Meeting on Women’s Cancer, SGO, Phoenix, AZ March 18 – 21, 2022 Accepted Poster Presentation
    • Encore presentation: Deutshcer Krebskongress 2022, Nov13-16– presented by Lars Hanker
  • Ana Oaknin, Lucy Gilbert, Anna Tinker, Wei Guo, Ellie Im, Bhavana Pothuri. Time Course of Adverse Events During Dostarlimab Treatment in Patients with Recurrent or Advanced Endometrial Cancer in the GARNET Trial, 22nd ESGO Hybrid Meeting, Oct 23–25, 2021 E-poster presentation
  • Ana Oaknin, Lucy Gilbert, Anna V Tinker, Jubilee Brown, Cara Mathews, Joshual Press, Renaud Sabatier, David O’Malley, Vanessa Samouëlian, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatgae, Rebecca Kristeleit, Charles Leath III, Jennifer Veneris, Tao Duan, Ellie Im, Bhavana Pothuri. Dostalimab in advanced/recurrent mismatch repair deficient/microsatellite instability high or proficient/stable endometrial cancer: the GARNET study, 22nd European Congress on Gynaecological Oncology Hybrid Meeting, Prague, Czech republic and Virtual, October 23-25, 2021 – Abstract presentation 272
  • Lucy Gilbert, Ana Oaknin, Anna V. Tinker, Renaud Sabatier, Valentina Boni, David M. O’Malley, Sharad Ghamande, Linda Duska, Prafull Ghatage, Wei Guo, Ellie Im, Bhavana Pothuri. Immune-Related Endpoints of the Mismatch Repair Deficient (dMMR) and Proficient (MMRp) Endometrial Cancer Cohorts from the Garnet Study, CANO/ACIO Virtual Annual Conference taking October 21-24, 2021 , Poster No. P-21, Encore poster presentation presented by Dr Lucy Gilbert
  • Ana Oaknin, Lucy Gilbert, Anna V. Tinker, Jubilee Brown, Cara Mathews, Joshua Press, Renaud Sabatier, David O’Malley, Vanessa Samouelian, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatage, Rebecca Kristeleit, Charles Leath III, Xinwei Han, Sujatha Kumar, Tao Duan, Ellie Im, Bhaavana Pothuri. Analysis of anti-tumor activity of dostarlimab by tumor or mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET Trial, ESMO Virtual Congress Sep 16 – 21, 2021 Poster presentation #76-P
    • Encore presentation, 7th Biennial Asian Society of Gynecologic Oncology, Nov 25 – 27, 2021, presented by Audrey Chang Poster E02
  • Ana Oaknin, Lucy Gilbert, Anna V. Tinker, Jubilee Brown, Cara Mathews, Joshua Press, Renaud Sabatier, David M. O’Malley, Vanessa Samouëlian, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatage, Rebecca Kristeleit, Charles Leath III, Jennifer Veneris, Tao Duan, Ellie Im, Bhavana Pothuri. Antitumor activity of dostarlimab in patients with advanced or recurrent mismatch repair–deficient or proficient–cancer by prior therapy: Results from the GARNET study, IGCS Rome & Virtual Annual Global Meeting, Aug 30 – Sept 2, 2021
    • Encore Presentation, ASGO November 25-27, 2021 Poster E09, presented by Yoshiaki KawanoE09
  • *Ulacia, Flores, Paola, McLennan, Stewart, Gilbert, Lucy, Rosaire, Mongrain. Three Dimensional Reconstruction of the Female Pelvic Organs for Biomechanical Modeling and device testing, European Society of Biomechanics (ESB 2021), Italy – Virtual Meeting, July 11 – 14, 2021. Podium Presentation
  • David M. O’Malley, Ana Oaknin, Usula A. Matulonis, Gina M Mantia-Smaldone, Peter Lim, Cesar Castro, Diane Provencher, Sanaz Memarzadeh, Patick A. Zweidler-McKay, Jiuzhou Wang, Brooke Esteves, Kathleen N Moore, Lucy Gilbert, Mirvetuximab soravtansine, a folate receptor alpha (FRα) – targeting antibody-drug conjugate ( ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer – final analysis, ASCO Annual Meeting (virtual), June 4 – 8, 2021 – Oral Presentation [publication 5504]
  • Karen Cadoo, Fiona Simpkins, Cara Mathews, Ying L. Liu, Diane Provencher, Colleen McCormick, Adam C. ElNaggar, Alon D. Altman, Lucy Gilbert, Destin Black, Nashwa Kabil, James Bennett, Hong Yu, Jiefen Munley, Carol Aghajanian. Olaparib Treatment for Platinum-Sensitive Relapsed Ovarian Cancer by BRCA Mutation and Homologous Recombination Deficiency Status: Phase II LIGHT Study Primary Analysis, ASCO June 4 – 8, 2021, Poster discussion session [publication 5515]
  • Valentina Boni, Ira Winer, Lucy Gilbert, Ulka N. Vaishampayan, Seth D Rosen, Jameel Muzaffar, Anna Sprearfico, David F McDermott, Quincy Chu, Olivier Dumas, Aman Chauhan, Arvind Chaudhry, Piotr Tomczak, Debora S Bruno, Yangchun Du, Ilda Bidollari, Jessicca Rege, Marc S Ernstoff, James F Strauss, Vamsidhar Velcheti, Artistry – 1: nemvalelulkin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors, ASCO Annual Meeting (virtual), June 4 – 8, 2021 – poster discussion session [Publication #2513]
  • Ainhoa Madariaga, Swati Garg, Nairi Tchrakian, Neesha C Dhani, Waldo Jimenez, Stephen Welch, Helen MacKay, Josee-Lyne Ethier, Lucy Gilbert
  • Angela Rodriguez, Valerie Bowering, Blaise Clarke, Tracy Stockley, Xuan Li, Lisa Wang, Smitha Udagani, Amit M Oza, Stephanie Lheureux. Phase II trial assessing niraparib with or without dostarlimab ( anti-PD-1) in recurrent endometrial carcinoma ASCO Annual Meeting (virtual), June 4 – 8, 2021, poster presentation, published in Journal of Clinical Oncology 2021, 38(15) suppl.
  • Cara Mathews, Fiona Simpkins, Karen Cadoo, Ying Liu, Diane Provencher, Colleen McCormick, Adam ElNaggar, Alon D. Altman, Lucy Gilbert, Destin Black, Nashwa Kabil, James Bennett, Jiefen Munley, Hong Yu, Carol Aghajanian. Olaparib treatment in patients with platinum-senstive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: overall survival resuls II LIGHT study, ASCO 2021, published in Journal of Clinical Oncology 2021 38(15), suppl
  • David M. O’Malley, Ana Oaknin, Ursula A. Matulonis, Gina M. Mantia-Smaldone, Peter Lim, Cesar Castro, Diane Provencer, Sanaz Memarzadeh, Patick A Zweidler-McKay, Jiuzhou Wang, Brooke Esteves, Kathlln N. Moore, Lucy Gilbert. Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-durg conjugate (ADC), in combination with bevacizumab in patients with platinum-agnostic ovarian cancer – final analysis, ASCO 2021, published in Journal of Clinical Oncology 2021 38(15), suppl
  • Valentina Boni, Ira Winer, Lucy Gilbert, Ulka N. Vaishampayan, Seth D Rosen, Jameel Muzaffar, Anna Spearafico, David F. McDermott, Quicny Chi, Olivier Dumas, Aman Chauhan, Arvicn Chaudhry, Piotr Tomczak, Debora S. Bruno, Yangchun Du, Ilda Bidollari, Jessicca Rege, March S. Ernstoff, James F Stauss, Vasidhar Velcheti. ASCO 2021, published in Journal of Clincial Oncology 2021 38 (15), supp
  • *S. Piedimonte, A. Schiavi , J. Power , E. Ambrosio , R. Konci , E. Weber , W. Foulkes , L. Palma , L. Gilbert , K. Jardon , X. Zeng, BRCA Testing with High Grade Serous Ovarian Cancer: Gyn-Oncologist Initiated Testing Compared to Genetics Referral, International Symposium on Hereditary Breast and Ovarian Cancer, Virtual Meeting May 4 – 7, 2021
  • Ana Oaknin, Lucy Gilbert, Ann V Tinker, Renaud Sabatier, Valentina Boni, David O’Malley, Sharad Ghamande, Linda Duska, Prafull Ghatage, Wei Guo, Ellie Im, Bhavana Pothuri. Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair Deficient or Proficient Endometrial Cancer: Results from GARNET, Hematology Oncology Pharmacy Association Annual Meeting (Virtual) April 13-17, 2021 Oral Presentation – [Abstract #CT11], Journal of Hematology Oncology Pharmacy, March 2021, Vol 1
    • Encore Presentation, 22nd European Congress on Gynecological Oncology (ESGO), Prague, Czech Republic, Virtual Oct 23 – 25, 2021
    • Encore Presentation, Heartland Association of Gynecologic Oncology 2021, Sept 17-18 –Poster presentation
  • Ana Oaknin, Lucy Gilbert, Anna Tinker, Wei, Guo, Ellie Im, Bhavana Pothuri, The Time Course of Adverse Events During Dostarlimab Treatment in Mismatch Mutation Repair Deficient and Proficient Endometrial Cancer Patients in the Garnet Trial, 46th Oncology Nursing Society Virtual Congress, April 20, – 29, 2021, virtual presentation, Oncology Nursing Forum, 48 (2): 5
    • Encore Presentation, Heartland Association for Gynecologic Oncology 2021, September 17-18 [Poster presentation]
    • Encore Presentation, Clinical Oncology Society of Australia (COSA), Nov 16, 2021, to be presented by Ashish Banerjee
  • Ana Oaknin, Lucy Gilbert, Ann V Tinker, Renaud Sabatier, Valentina Boni, David O’Malley, Sharad Ghamande, Linda Duska, Prafull Ghatage, Wei Guo, Ellie Im, Bhavana Pothuri, Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair Deficient or Proficient Endometrial Cancer: Results from GARNET, Hematology Oncology Pharmacy Association Annual Meeting (Virtual) April 13-17, 2021 Oral Presentation – [Abstract #CT11], Journal of Hematology Oncology Pharmacy, March 2021, Vol 1
    • 22nd European Congress on Gynecological Oncology (ESGO), Prague, Czech Republic, Virtual Oct 23 – 25, 2021
  • Ana Oaknin, Lucy Gilbert, Anna V Tinker, Renaud Sabatier, Valentina Boni, David O’Malley, Sharad Ghamande, Linda Duska, Prafull Ghatage, Wei Guo, Ellie Im, Bhavana Pothuri. Interim Analysis of the Immune-Related Endpoints of the Mismatch Repair Deficient (dMMR) and Proficient (MMRp) Endometrial Cancer Cohorts From the GARNET Study, SGO Virtual Annual Meeting on Women’s Cancer, March 19 – 25, 2021Poster (10900) and Oral Feature Poster
    • Encore presentations:
      • 11th Charité Mayo Conference, May 5 – 8, 2021 Berlin and Virtual
      • British Gynaecological Cancer Society 2021 Virtual Meeting , May 13 – 14, 2021
      • HAGO, Madison WI, Sept 17 – 18, 2021
      • ESMO, Virtual, Sept 17 – 21, 2021
      • Deutsche Gesellschaft fur Hamatologie und Medizinische Onkologie Annual Meeting, Berlin, Oct 1 – 4, 2021, presented by Lars Hanker
      • Associazione Italiana d’Oncologia Medica (AIOM), Rome, Italy Oct 22 -24, 2021, to be presented by Giuseppe Curigliano
      • 48th Annual Abstract Clinical Oncology Society of Australia (COSA), Nov 16-18, 2021, to be presented by Ashish Banerjee
      • 7th Biennial Asian Society of Gynecologic Oncology (ASGO), Nov 25-27, 2021, to be presented by Yoshiaki Kawano
  • Karen Cadoo, Fiona Simpkins, Cara Mathews, Alon D, Altman, Lucy Gilbert, Ying Lium, Destin Black, Jiefen Munley, Nashwa Kabil, James Bennett, Hong Yu, Carol Aghajanian, Oliparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: secondary results from the Phase II LIGHT, SGO Annual Meeting on Women’s Cancer, Mar 19 – 25, 2021 – poster presentation and supplement (Poster 10900)
  • Ira Winer, Lucy Gilbert, Ulka N. Vaishampayan, Seth D. Rosen, Christopher J. Hoimes, Jameel Muzaffar, Anna Spreafico, David McDermott, Quincy Chu, Olivier Dumas, Aman Chauhan, Arvind Chaudhry, Piotr Tomczak, Valentina Boni, Debora S. Bruno, Kelly K. Curtis, Yan Wang, Elizabeth Dorn, Jessicca Rege, Yangchun Du, Ilda Biodallari, Lei Sun, Emily Putiri, Heather C. Losey, Bruce J. Dezube, Marc. S Ernstoff, Vamsidhar Velcheti, James Strauss. Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTY-1 Trial, Society for Immunotherapy of Cancer (SITC) 35 Annual Meeting – Virtual Meeting, November 10–15, 2020 – poster presentation #347
  • *Lawrie Shabahsian. Timothé Reveil. Olga Bass, Jose Joao Mansure, Ahmed Nazer, Lai Jiang, Kris Jardon, Xing Zeng, Mary Tsatsoumas, Claudia Martins, Ian Comeau, Robert Hemmings, Fadi Aris, Jocelyne Arseneau, Lili Fu, Tuyet Ton Nu, Vesela Ivanova, Jing Leng, Ioannis Ragoussis, Celia Greenwood, Lucy Gilbert, Pre-operative risk stratification of endometrial cancers using genomics, GOC Virtual AGM Oct 14, 2020 – oral presentation
  • Oaknin,Ana, Gilbert,Lucy, Tinker,Anna V, Sabatier, Renaud, Boni,Valentina O’Malley, David, Ghamande,Sharad, Duska,Linda, Ghatage,Prafull, Hadi Danaee, Weil Guo, Ellie Im, Pothuri, Bhavana. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer: Results from Garnet, ESMO Virtual Congress 2020, Science Weekend, September 19-21, 2020 – Oral Presentation
    • Encore presentation: ESGO SoA Virtual Conference, Copehagan, Denmark Dec 14 – 16, 2020 – eposter
  • Ulka N Vaishampayan, Jameel Muzaffar, Vamsidhar Velcheti, Ira Winer,Christopher J Hoimes, Seth D Rosen, Anna Spreafico, David McDermott,Quincy Siu Chum Olivier Dumas, Lucy Gilbert, Hal Hirte, Kelly K Curtis, Yangchun Du, Ilda Bidollari, Lei Sun, Emily Putiri, Heather C Losey, Bruce J Dezube, Marc S Ernstoff, ALKS 4230 Monotherapy and in Combination With Pembrolizumab (pembro) in Patients (pts) With Refractory Solid Tumors (ARTISTRY-1), ESMO Virtual Congress 2020 Science Weekend, September 19-21, 2020 – Mini Oral Presentation
  • David M. O’Malley, Debra L. Richardson, Ignace Vergote, Lucy Gilbert, Lainie P Martin, Gina M Mantia-Smaldone, Cesar M Castro, Diane Provencher, Ursula A Matulonis, Kathleen N Moore Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer, ESMO Virtual Congress 2020, Science Weekend, September 19-21, 2020 – E-poster presentation
  • Ana Oaknin, Anna Tinker, Lucy Gilbert, Vanessa Samouëlian, Cara Mathews, Jubliee Brown, Wei Guo, Hadi Danaee, Ellie Im, Renaud Sabatier. Safety and efficacy of the anti-PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer Heartland Association of Gynecological Oncology (HAGO), Sept 10-12, 2020 Madison, WI – Oral Presentation
  • Lucy Gilbert, Ana Oaknin, Ursula A. Matulonis, Gina Mantia-Smaldone, Peter C Lim, Cesar Martin Castro, Diane M. Provencher, Sanaz Memarzadeh, Jiuzhou Wang, Brooke Esteves, Patrick Zweidler-McKay, Kathleen N. Moore, David M. O’Malley, Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer, ASCO Virtual Scientific Meeting May 29-June 2,2020 Abstract 6004 – Virtual Oral Presentation by Lucy Gilbert, presenter
  • Vaishampayan UN, Muzaffar J, Velcheti V, Hoimes CJ, Gilbert L, McDermott D, Spreadfico A, Chu Q, Curtis KK, Du Y, Mackenzie H, Sun L, Putrir E, Losey HC, Dezube BJ, Ernstoff MS, ALKS 4230, an engineered IL-2fusion protein, in monotherapy dose-escalation and combination therapy with pembrolizumab in patients with solid tumors : ARTISTRY – 1 trial, Society for Immunotherapy of Cancer (SITC), National Harbor, MD, November 6-10, 2019 – Oral or Poster presentation
  • David M. O’Malley, Debra L. Richardson, Ignace Vergote, Lucy Gilbert, Lainie P Martin, Gina M Mantia-Smaldone, Cesar M Castro, Diane Provencher, Ursula A Matulonis, Karim Malek, Kathleen N Moore, Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugatge (ADC), in combination with carboplatin and bevacizumab: Initial results from a Phase 1b study in patients (pts) with ovarian cancer, ESMO Congress, Barcelona, Spain September 12 – October 1, 2019 – Poster presentation
  • David M. O’Malley, Ursula A. Matulonis, Michael J. Birrer, Cesar Martin Castro, Ignace Vergote, Lainie P. Martin, Gina Mantia-Smaldone, Lucy Gilbert, Antonio González-Martín, Raquel Bratos, Brooke Esteves, Karim S. Malek, Kathleen N. Moore; Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study. Chicago, Illinois, May 31-June 4, 2019 – Poster Presentation
  • Ana Oaknin, Susan Ellard, Charles Leath III, Wei Guo, Asharon Lu, David Jenkins Kristen McEachern, Kai Yu Jen, Steven Dunlap, Ellie Im, Lucy Gilbert, “Preliminary safety, efficacy, and PK/PD characterization from Garnet, a phase 1 clinical trial of the anti-PD-1monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer, ESMO, Munich, Germany, Oct 19 -23, 2018 – Poster Presentation (935PD)
  • Ursula A. Matulonis, Kathleen N Moore, Lainie P Martin, Ignace Vergote, Cesar M Castro, Lucy Gilbert, Karim Malek, Michal J Birrer, David M O’Malley, Mirvetuximab soravtansine, a folate receptor alph (FRα)-targeting antibody-drug conjugae (ADC), with pembrolizumab in platinum-resistant ovarin cancer (PROC): Initial results of an expansion cohort from FORWARD II, a Phase Ib study, ESMO, Munich, Germany, Oct 19-23, 2018 – Poster Presentation
  • Joanne Alfieri, Reem Albeesh, Guy-Anne Turgeon, José João Mansure, Lili Fu, Jocelyne Arseneau, Kris Jardon, Xing Zeng, Lucy Gilbert, Luis Souhami, FASTRO, What is the right adjuvant treatment of pelvic confined stage III endometrial cancer? Long-term results from a single institution, 17th Biennial Meeting of International Gynecologic Cancer Society (IGCS), Kyoto, Japan, September 14-16, 2018 – Poster Presentation.
  • *S. Piedimonte, A. Schiavi , J. Power , E. Ambrosio , R. Konci , E. Weber , W. Foulkes , L. Palma , L. Gilbert , K. Jardon , X. Zeng, Uptake of BRCA Testing in High Grade Serous Ovarian Cancer: A comparison of trends between genetics referral and gyn-oncologist initiated testing, 17th Biennial Meeting of International Gynecologic Cancer Society (IGCS), Kyoto, Japan, September 14-16, 2018 – Poster Presentation
  • *Annie Leung, Olga Basso, Cristina Mitric, Xing Zeng, Kris Jardon, Giovanni Artho, Caroline Reinhold, Lucy Gilbert, “Choosing Wisely” in managing low risk endometrial cancer patients: Institutional experience in decreasing routine pre-operative MRI, 74th SOGC Annual Clinical and Scientific Conference, Victoria, BC., June 26-29, 2018 – Oral presentation, accepted as “Best of Three” Oral Presentations.
  • David M. O’Malley, Lainie P. Martin, Lucy Gilbert, Ignace Vergote, Ursula A. Matulonis, Michael J. Birrer, Cesar Castro, Karim Malek, Antonio González Martin, Kathleen N. Moore, Mirvetuximab soravtansine, a folate receptor alpha (FR)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: maturing safety and activity profile from the FORWARD II Phase 1b study. 2018 ASCO Annual Meeting, McCormick Place, Chicago, Il June 1 – 5, 2018, Publication Number Publication: 5549 – Poster Presentation.
  • Victor Moreno, Maria-Pilar Barretina-Ginesta, Wei Guo, Sharon Lu, David Jenkins, Kristen McEachern, Vienna Reichert, Steven Dunlap, Ellie Im, Lucy Gilbert, Anna Oaknin Benzaquen, Charles Leath III, Janakiraman Subramanian, Prelininary safety, efficacy and PK/PD characterization from GARNET, a phase 1 clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced NSCLC and MSI-H endometrial cancer. AACR Annual Meeting 2018, Chicago, Illinois, April 14-18 – Poster Presentation
  • Ursula A Matulonis, Kathleen N Moore, Lainie P Martin, Ignace Vergote, Cesar M Castro, Lucy Gilbert, Anna Berkenblit, Michael J Birrer, David m O’Malley. Initial safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in platinum-resistant epithelial ovarian cancer patients, SGO Annual Meeting, New Orleans, Lousiana, March 24-27, 2018 – Poster Presentation
  • Jing Wang, Zhi-Yi Zhang, Mansoor R. Mirza, Lucy Gilbert, Michel Fabbro, Anna Tinker, Xiaodong Wang, Andres Redondo, Jonathan S. Berek, Linn Wölber, Helen S. Pentikis, Kathleen Moore, Domenica Lorusso, Benedict Benigno, Sebastien J. Hazard, Philippe Follana, Bobbie J. Rimel, Ursula A. Matulonis, Shefali Agarwal and Vikram Kansra, The Exposure-Response Relationship of Niraparib in Patients with gBRCAmut and Non-gBRCAmut: Results from the Phase 3 ENGOT-OV16/NOVA Trial. ESMO 2017 Annual Meeting, Madrid, Spain, September 8-12, 2017 – Poster Presentation
  • Moore K, Matulonis U, O’Malley D, Konner J, Martin L, Perez Raymond, Bauer T, Gilbert L, Meward S, Oza A, Ruiz-Soto R, Mirrer M, Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and Safety Analyses in phase I pooled expansion cohorts, ASCO Annual Meeting, Chicago, Illinois, June 2-3, 2017. J Clin Oncol 35, 2017 (suppl;abst 5547)
  • Mirza M, Monk B , Gil-Martin M, Gilbert L, Canzler U, Follana P, Waters J , Kridelka F, Levy T, Benigno B, Woie K, Provencher D, Lück H J, Casado Herráez A , Lesoin A, Buscema J, Hellman K, Rimel B, Hazare S, Matulonis U, Efficacy of Niraparib in Patients with Recurrent Ovarian Cancer with Partial Response to the Last Platinum-Based Chemotherapy, ASCO Annual Meeting, Chicago, Illinois, June 2 -3, 2017, J Clin Oncol 35, 2017 (suppl; abstr 5517) – Poster Presentation
  • Del Campo J, Mirza M, Berek J , Provencher D, Emons G, Fabbro M, Lord R, Colombo N, Petru E, Wenham R, Herrstedt J, Gilbert L, Heubner M, Gonzalez Martin A, Follana P, Benigno B, DØrum A, Rimel Bj, Hazard S, Matulonis U, The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum-resistant ovarian cancer, ASCO Annual Meeting, Chicago, Illinois, June 2-3 2017 – J Clin Oncol 35, 2017 (Suppl; abstr 5560) ─ Poster Presentation
  • O’Malley D, Moore K, Vergote I, Martin L, Gilbert L, Gonzalez Martin A, Malek K, Birrer M, Matulonis U, Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer, ASCO Annual Meeting, Chicago, Illinois, June 2-3 2017, J Clin Oncol 35, 2017 (Suppl; abstr 5553) ─ Poster Presentation.
  • Matulonis U, Herrstedt J, Oza A, Mahner S, Redondo A, Fabbro M, Ledermann J, Lorusso D, Vergote I, Rosengarten O, Reinthaller A, Madry R, Monk B J, Dorum A, Tinker AV, DuBois A, Gonzalez Martin A, Follana P, Berek J, Gilbert L, Benigno B, Rosenberg P, Rimel BJ , Buscema J, Balser J, Agarwal S, Mirza MR, ENGOT-OV16/NOVA: A Randomized, double-blind Phase 3 Trial of Niraparib maintenance therapy versus placebo in women with Platinum-sensitive recurrent ovarian cancer 16th Biennial Meeting of the IGCS and IGCS 2016 Scientific Program in Lisbon, Portugal, October 29-31, 2016 – Presentation
  • *Piedimonti S, Richer L, Arseneau J, Fu L, Jardon K, Gilbert L, Zeng X, Defining a subset of early endometrial cancer patients with isolated tumor cells and micrometastasis following pelvic lymph node dissections, 16th Biennial Meeting of the IGCS and IGCS 2016 Scientific Program in Lisbon, Portugal, October 29-31, 2016 – E-Poster presentation
  • *Albeesh Reem, Alfieri Joanne, Mansure Jose, Turgeon Guy-Anne, Fu, Lili, Arseneau Jocelyne, Jardon Kris, Gilbert Lucy, Souhami Luis, Outcomes of adjuvant therapy in stage 3 endometrial cancer confined to the pelvis, ASTRO 58th Annual Meeting, Boston, Massachusetts, September 25-28, 2016 – Poster Presentation
  • El-Zein Mariam, Bouten Sheila, Louvanto Karolina, Gilbert Lucy, Gotlieb Walter, Hemmings Robert, Behr Marcel, Franco Eduardo, Validation of a new HPV self-sampling device: the cervical and self-sampling in screening (CASSIS) Study, EUROGIN 2016, Salzburg, Austria, June 15-18, 2016 – Oral Presentation
  • Gilbert L, Lio S, Arseneau J, Assigning site of origin in high grade serous cancer – Bridging the gap between research and clinical practice IGCS 4th IGCS Regional Meeting on Gynecologic Cancers, Santiago Chile, May 11, 2015 – Oral Presentation
  • Covens, B. Higgins, S. Verma, P. Bessette, J. Bin, L. Gilbert, P. Hoskins, D. Provencher, P. Ghatage, D. Warr, M. Majdan, J.-F. Pouliot. Fosaprepitant as Salvage Treatment of Chemotherapy-Induced Vomiting (CIV) in Breast and Ovarian Cancer, MASCC 2014 Meeting, Miami June 26, 2014 Abstract Presentation.
  • *Piedimonte S, Basso O, Ramanakumar AV, Gilbert L. Can predictive models reduce the burden of unnecessary tests in a program of ovarian cancer detection? Society of Obstetrics and Gynaecology Annual Clinical Meeting, June 11, 2013, Calgary, Alberta, Canada. Best Oral Presentation by a HealthCare Student Award – Oral Presentation.
  • X Zeng, L Gilbert, G Artho, J Arsenault, J Sturgeon, K Jardon, Primary yolk sac tumor of the endometrium managed with chemotherapy alone, European Society of Gynaecological Oncology 18th International Meeting in Liverpool, Oct 2013 – Poster Presentation.
  • Gilbert L, Martins C et al. Expression of the Metastasis Suppressor gene KAI1 in melanoma of the female tract, GOC 32nd annual general meeting, Vancouver, Canada, June 24-26, 2011 – Oral Presentation.
  • Gilbert, L. Jardon, K. Grigorie, M. Martins, C. Lisbona, R. Querleu, D. Short Protocol Intraoperative Sentinel Lymph Node Identification in Vulvar Cancer. Eur. Soc. Gyn Oncol – Milan, 2011 – Poster Presentation
  • Gilbert L et al. DOvE—Detecting OVarian cancer Earlier: A Pilot Project. 13th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), Prague, Czech Republic, October 23-26, 2010.
  • *Nourmoussavi M, Gilbert L, Mortality and morbidity associated with surgery for endometrial cancer in women over 70 years. 13th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), Prague, Czech Republic, October 23-26, 2010